AUTHOR INDEX

Al-Ahmad, A., 3
Alexander, D. C., 463
Alexander, S. R., 451
Al-Uzri, A. Y., 451
Anastasio, P., 262, 282, 323
Anderson, M.-L. E., 231
Andreucci, M., 251, 317
Andreucci, V. E., 251
Antoniello, S., 317
Appel, G. B., 403
Arima, S., 535
Auletta, M., 317
Avner, E. D., 430

Bakir, A. A., 334
Barbour, M. M., 66
Bellini, L., 262
Belson, A., 451
Berg, A., 222
Bergere, V., 470
Boonstra, A., 580
Border, W. A., 563
Bragantini, L., 346
Branch, D., 419
Brendolan, A., 346
Briscoe, D. M., 508

Cadnapaphornchai, M. A., 157
Callendar, C. O., 419
Calvet, J. P., 107
Cao, Z., 554
Capodicasa, L., 262, 323
Cárdenas, A., 308
Chadha, V., 480
Chiaramonte, S., 346
Chiricone, D., 262
Cianciaruso, B., 317
Cirillo, E., 262
Cirillo, M., 221, 262, 282
Colzani, S., 291
Cooper, M. E., 554
Cotrufo, M., 282
Crawford, P. W., 329
Crepaldi, C., 346

Daelemans, R. A., 204
D'Amico, M., 291
Daumit, G. L., 367
Davis, I. D., 430
Davison, J. M., 173
DeBroe, M. E., 204
Deierhoi, M. H., 47
De Jong, P. E., 580
Dell, K. M., 430
Dell' Aquila, R., 346
Del Vecchio Blanco, C., 323
De Napoli, N., 221, 323
De Santo, L. S., 278, 282
De Zeeuw, D., 580
D'Haese, P. C., 204
Dharnidharka, V. R., 521
Diener-West, M., 377
Di Filippo, S., 291
Di Iorio, B., 282
Dissegna, D., 346
Di Stasio, V., 262
Drummer, C., 239
Dunea, G., 334
Durai, T. T., 411

Emmett, L., 498

Favazzi, P., 262
Federico, S., 251
Fernandez, J. S., 25
Fine, R. N., 429
Fink, J. C., 356
Fiorillo, M., 317
Fischbach, M., 470
Fivush, B. A., 463
Fogo, A. B., 544
Frangiosa, A., 262, 282, 323
Franz, M., 298
Friedman, E. A., 411
Frøkiær, J., 231
Furth, S. L., 463

Gallichio, M. H., 47
Garg, P. P., 377
Gaspare De Santo, N., 221, 262, 282, 323
Ginès, P., 308
Gjerde, E.-A. B., 222
Goral, S., 213
Grantham, J. J., 107
Gross, P., 269
Gunukula, S. R., 52
Gurevich, A. K., 157

Haffner, D., 490
Hager, H., 231
Halevy, D., 403
Hall, M. B., 419
Harmon, W. E., 521
Helderman, J. H., 213
Henrich, W. L., 356
Hörl, W. H., 298
Hostetter, T. H., 573
Hsu, S. I-H., 411
Hudson, S. L., 47
Hwang, W., 463

Ibrahim, H. N., 573
Iorio, L., 278
Ito, S., 535

Juknevicius, I., 573

Katz, A. I., 173
Keane, W. F., 533
Kempski, O., 303
Klahr, S., 133
Klotman, P. E., 394
Kocheril, A. G., 57
Konstam, M. A., 3
Korr, K. S., 36
Kurtzman, N. A., 79, 94, 257
Kwon, T.-H., 231

La Greca, G., 346
Levin, N. W., 327
Lewis, E. J., 124
Lewis, J., 124
Lindheimer, M. D., 173
Locatelli, F., 291
Loguercio, C., 323

Ma, L-j., 544
McKindley, D. S., 66
Magri, P., 317
Mailloux, L. U., 146
Manzoni, C., 291
Meneton, P., 81
Menouer, S., 470
Milan, M., 346
Molino, D., 262
Monahan, M., 394
Musone, D., 317

Nandakumar, M., 411
Navis, G., 580
Nejsum, L. N., 231
Neu, A. M., 463
Nielsen, S., 231
Nissenson, A. R., 190
Noble, N., 563
Norris, K. C., 362

Oh, Y. S., 81
Owen, W. J., Jr., 327, 411

Pacher, R., 273
Papalia, T., 221, 323
Pascale, C., 262
Perna, A., 262
Pollastro, R. M., 262
Powe, N. R., 367, 377, 463
Provot, E., 470

Radhakrishnan, J., 403
Ramanathan, V., 213
Ramirez, S. P. B., 411
Reed, R. K., 222
Reitman, A., 36
Rodighiero, M., 346
Ronco, C., 346
Rosenberg, M. E., 573
Rubin, K., 222

Sabatini, S., 94, 244
Sadaniantz, A., 1, 25
Salem, D. N., 3
Samsonov, D. V., 508
Sanchez, C. P., 441
Santoro, A., 286
Sarnak, M. J., 3
Saviano, C., 262
Schaefer, F., 490
Schrier, R. W., 157
Sepe, J., 262
Sho, M., 508
Somma, G., 317
Sorrell, V. L., 13
Spodick, D. H., 52
Stellato, D., 262, 282
Sweeney, W. E., 430
Szczech, L. A., 386

Tanji, N., 394
Tareen, N., 362
Tejani, A., 429, 498
Terzic, J., 470
Thornhill-Joynes, M., 362
Tong, E. M., 190
Torraca, S., 317

Violi, F., 278

Warady, B. A., 480
Warnock, D. G., 81, 593
Woloszczuk, M., 298

Yorgin, P. D., 451

Zucchelli, P., 286

SUBJECT INDEX

AABI (ankle-arm blood pressure index) in CAD, 18
Abacavir, 388
Abciximab, 32-33
Aberrant biology of TGF-β, 564
Absorption, CV drug, in renal disease, 66-67
Abundance of aquaporin-2, regulation of, 233-234
Access
  to cardiac procedures, factors affecting urban renal disease patients', 367-376
  see also Access to dialysis; Vascular access
Access to dialysis
  clotting of, due to rHuEPO therapy, 196
  peritoneal, at Vicenza dialysis center, 348
  see also Vascular access
ACE, *see* Angiotensin-converting enzyme
Acidosis
  metabolic, and growth retardation in dialyzed ESRD children, 465
  see also Distal renal tubular acidosis
Acquired immunodeficiency syndrome, *see* HIV-associated nephropathy in urban population; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients
Acquired neurogenic diabetes insipidus (NDI), aquaporin-2 in, 234-236
Activated T cells, nuclear factor of, as calcineurin target, 510-511
Activator inhibitor-1 (PAI-1), ANG II and, in GS, 548
Acute and chronic rejection of pediatric renal transplantation, 498-507
  acute rejection, *see* Acute rejection of pediatric renal transplantation
  chronic rejection, 500-501, 504-506
  cytokines in, 498-501
  immunosuppression and, *see* Immunosuppression in pediatric renal transplantation
Acute coronary syndrome in renal disease, 25-38
  clinical presentation of, 25-26
  coronary risk factors for, 25
  diagnosis of, 26-28
  MI and, *see* Acute myocardial infarction with ST segment elevation in renal disease, management of; Non-Q wave myocardial infarction in renal disease, management of
  pathology of, 26
  unstable angina and, *see* Unstable angina in renal disease, management of
Acute myocardial infarction (MI) with ST segment elevation in renal disease, management of, 25, 28-33
  medical management of, 28-29
  revascularization procedures for, 30-33
Acute rejection of pediatric renal transplantation, 498-504
  cytokines in, 498-501
  diagnosis of, 501, 504-505
  frequency and incidence of, 501-502
  histopathology of, 502
  immunosuppression and, 502-504; *see also* Immunosuppression in pediatric renal transplantation
  molecular pathology of, 500-502
Acute renal failure (ARF)
  contrast induced, *see* Contrast induced renal failure
  CsA effects in, 75
  treatment of, at Vicenza dialysis center, 352-353
  with uremic pericarditis, 53-54
  see also Acute renal failure, edema with
Acute renal failure (ARF), edema with, 251-256
  in burn injury, 253-254
  in CHF and MODS, 253
  in glomerulonephritis and idiopathic nephrotic syndrome, 252-253; *see also* Nephrotic edema
  local factors in, 241
  systemic factors in, 251-252
  therapy of, 254-255
Acyclovir, 523-526
Adaptations to pregnancy, *see* Renal physiological adaptations to pregnancy
Adefovir, 386, 388, 390-391
Adenosine nuclear scanning, 15, 16, 22
Adenosine triphosphatase, *see* H-ATPase; H,K-ATPase; Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and
Adequacy of dialysis
  aspects of, beyond Kt/V at Vicenza dialysis center, 350-352
  and dialysis dose, 204-207
  see also Adequacy of HD; Adequacy of pediatric CPD for ESRD
Adequacy of HD
  intermediate HD outcomes in U.S. and Singapore, compared, 415
  pediatric HD, 475-477
Adequacy of pediatric CPD for ESRD, 480-489
  and characteristics of peritoneal transport, 482
  dose and, 480-481
  outcome and, *see* Outcome of pediatric CPD for ESRD
  recommendations on, 480
  solute clearance and, *see* Solute clearance on pediatric CPD
ADH (antidiuretic hormone), *see* Vasopressin
Administration routes for rHuEPO, 192-193
ADPKD, *see* Autosomal dominant polycystic kidney disease
α (alpha)-Adrenergic receptor antagonists, 162, 389
β (beta)-Adrenergic receptor antagonists
  for cyclic idiopathic edema, 247
  for heart failure with edema, 273, 276, 277
  for Na and water retention in CHF with cirrhosis, 157, 162
  progression of renal disease and, 593
  protective effects of, on RAS, 593
  for urban renal disease patients, 387, 389
  see also β-Adrenergic receptor antagonists for CV disease in renal disease *and specific β-adrenergic receptor antagonists*
β (beta)-Adrenergic receptor antagonists for CV disease in renal disease
  for acute coronary syndrome, 28, 33
  for arrhythmias, 58, 60-62
  for CAD, 19
  for heart failure, 8, 9
  pharmacology of, 68

Adriamycin, 235
Adsorption of pro-ANPs, *see* Atrial natriuretic factors, adsorption of, in uremia
Adult height, *see* rGH therapy for dialyzed ESRD children, effects of, on adult height
Adverse effects
of ACE inhibitors on renal function, 73-74
of antiretroviral drugs, 390-391
associated with water contaminants in HD, 471
of immunosuppressants, 510-514, 516
of rHuEPO, *see* Adverse effects of rHuEPO
of tetracyclines, 522
see also Anaphylactoid reactions; Toxicity *and specific drugs*
Adverse effects of rHuEPO, 198
in children, 456-457
African-Americans, *see* Urban renal disease
Age-related glomerulosclerosis (GS), regression of, with ACE inhibitors or AT_1 receptor antagonists, 550
AGT (angiotensinogen), functional genomics of, and RAS pathophysiology, 583-584
AIDS (acquired immuno-deficiency syndrome), *see* HIV-associated nephropathy in urban population; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients
Albumin
serum, as index of nutritional status of children on CPD, 486
see also Albumin infusions
Albumin infusions
for cirrhosis with ascites, 313-315
for edema, 252, 255, 259, 267
Alcohol abuse, urban renal disease and, 362
Aldose reductase inhibitors, 127
Aldosterone
deficiency in, in hyperkalemic dRTA, 96-97
role of renin-angiotensin II-aldosterone axis in cyclic idiopathic edema, 246-247
Aldosterone, progression of renal disease and, 573-579
hyperaldosteronism in renal failure, 573-576
interactions between ANG II and, in GS, 547
nonhemodynamic actions of, 576-577
Aldosterone receptor antagonists, 273, 276, 593, 587
Aldosterone resistance, *see* Pseudohypoaldosteronism; Pseudohypoaldosteronism type 1; Pseudohypoaldosteronism type 2
Alfacalcidol, 151, 445, 446
Allergies, *see* Anaphylactoid reactions
Allograft nephropathy, chronic, 215-216
Alpha (α)-adrenergic receptor antagonists, 162, 389
Alpha (α)-atrial natriuretic peptides (ANPs), 300, 301
Alpha (α)-tocopherol (vitamin E), 187, 224
Alpha (α)-trinositol (D-myo-inositol-1,2,6-triphosphate), 225, 227
Alprazolam, 389
Aluminum intoxication on dialysis, 207-210
Amantadine, 526
Ambulatory blood pressure (BP) monitoring
in CAD, 19-20
in ESRD, 151
Amiloride, 68, 70, 98-99, 600
Amino acid supplementation for growth-retarded dialyzed ESRD children, 466
Aminonucleoside, puromycin, 235, 236
Amiodarone, 58, 69, 389, 390
Amlodipine, 19, 69, 163, 389, 431
Amphetamines, 249
Amphotericin B, 103, 523, 524
Ampicillin, 524
Amprenavir, 389
Analgesics
abuse of, HIVAN and, 362
see also specific analgesics
Anaphylactoid reactions
to dialysis, 74-75
to radiographic contrast agents, 37-38
Anemia of ESRD
and growth retardation in dialyzed ESRD children, 465
see also entries beginning with acronym: rHuEPO
ANG, *see* Angiotensin (1-7); Angiotensin II
Angina pectoris
in acute coronary syndrome, 25
see also Unstable angina in renal disease, management of
Angiography and/or angioplasty, *see* Percutaneous coronary angiography and/or angioplasty, renal implications of
Angiotensin (1-7) [ANG (1-7)], 539-540
Angiotensin II (ANG II)
in cyclic idiopathic edema, 246-247
see also entries beginning with term: Angiotensin II
Angiotensin II (ANG II), progression of renal disease and, 535-543
AT_1 receptor-mediated action of ANG II, 536-537; *see also* AT_1 receptor(s) of ANG II
AT_2 receptor-mediated action of ANG II, 537-539; *see also* AT_2 receptor(s) of ANG II
renal effects of ANG II fragments and, 539-540
and role of ANG II in renal development, 539
Angiotensin II (ANG II) fragments, renal actions of, renal disease progression and, 539-540
Angiotensin II (ANG II) in GS, 544-553
ECM synthesis and degradation and, 548-549
glomerular hypertrophy and, 545-546
hemodynamic versus nonhemodynamic mechanisms of, 545
immune/inflammatory injury and, 546-547
interactions between aldosterone and, 547
PAI-1 and, 548
regression of GS with ACE inhibitors, 549-551
significance of RAS and related gene polymorphisms and, 547-548
Angiotensin II (ANG II) receptor antagonists
in CHF with cirrhosis, 157
for CV disease in renal disease, 9, 74-75
in cyclic idiopathic edema, 247
for diabetic nephropathy, 129
in prevention of pediatric ADPKD progression, 432
rHuEPO and, 216
for urban renal disease patients, 389
in UTO, 141, 142
see also AT_1 receptor antagonists; AT_2 receptor antagonists
Angiotensin II (ANG II) in tubulointerstitial injury, 554-562
apoptosis and, 560
cellular proliferation and tubular hypertrophy and, 559-560
monocyte/macrophage infiltration and, 558
nuclear factor κB and protein trafficking and, 559

osteopontin and, 557
RANTES and, 554, 559
SPARC and, 554, 557-558
TGF-β1 and, 554-557
TNF-α and, 558-559
tubulointerstitial fibrosis and, 554
Angiotensin-converting enzyme (ACE)
functional genomics of, and RAS pathophysiology, 582-583
see also Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme (ACE) inhibitors
for cyclic idiopathic edema, 247, 249
for diabetic nephropathy, 74, 126-129, 131
in fibrotic diseases, 563, 565, 566, 570
for heart failure with edema, 273, 276, 277
for HTN of pediatric ADPKD, 431, 432
in hypertensive pregnancy, 178
for Na and water retention in CHF with cirrhosis, 157, 162
rHuEPO and, 216
for urban renal disease, 336, 339, 341, 394, 401
in UTO, 139-142
see also Angiotensin-converting enzyme inhibitors, progression of renal disease and; Angiotensin-converting enzyme inhibitors for CV disease in renal disease *and specific angiotensin-converting inhibitors*
Angiotensin-converting enzyme (ACE) inhibitors, progression of renal disease and, 545, 586, 588
diabetic and nondiabetic renal disease, 584, 586-588
fibrotic diseases, 563, 564
GS, 545, 547, 549-551
protective effects of, *see* Protective effects of ACE inhibitors
tubulointerstitial injury and, 554-556, 559, 560
Angiotensin-converting enzyme (ACE) inhibitors for CV disease in renal disease
for CAD, 19, 22
for diabetic nephropathy, 74, 126-129, 131
in ESRD, 150, 183-194
for heart failure, 8-9
in percutaneous coronary intervention, 41
pharmacology of, 68, 73-75
Angiotensinogen (AGT), functional genomics of, and RAS pathophysiology, 583-584
Anion gap, hyperchloremic metabolic acidosis with normal, conditions associated with, 95
Anistreplase, 28
Ankle-arm blood pressure index (AABI) in CAD, 18
ANPs, *see* Atrial natriuretic peptide(s)
Antacids, 67
Antiarrhythmic agents, 57-59, 61, 62, 68, 387
see also specific antiarrhythmic agents
Antibiotics, 254
see also specific antibiotics
Anticoagulants (thrombolytics), 25, 28, 29, 33, 44, 60
see also specific anticoagulants
Antidiuretic hormone, *see* Vasopressin
Antihyperlipidemic therapy, *see* Hyperlipidemia in renal disease
Antihypertensive drugs
interaction between antiretroviral agents and, 387-390
in prevention of pediatric ADPKD progression, 431
see also Hypertension *and specific antihypertensive drugs*
Anti-inflammatory agents, *see* Nonsteroidal anti-inflammatory drugs *and specific anti-inflammatory agents*
Antilymphocyte globulin, 503
Antimicrobial agents for pediatric postrenal transplantation infections, 523-527
bacterial, 523
see also Viral infections, pediatric postrenal transplantation, management of
Antioxidants, 186-187, 434-435
Antiretroviral drugs for urban HIV-infected patients, renal dysfunction due to, 387-391
highly active, 394, 395, 398, 401
interaction between antihypertensive and, 387-390
renal effects of selected, 390-391
see also specific antiretroviral drugs
Antisense oligodeoxynucleotides (ODN), TGF-β, 143
Antithymocyte globulin, 503
Apical Na^+ transporters, *see* Renal apical Na^+ transporters, genetic disorders of
Apoptosis
in heart failure, 274, 275
in tubulointerstitial injury, 560
in UTO, 138-139
Aquaporin(s), 231-238
in pathogenesis of nephrotic edema, 265-266
see also specific aquaporins
Aquaporin-1 (AQP-1), 231, 232, 234, 265, 266
Aquaporin-2 (AQP2), 231-236
in diseases and/or conditions with altered water balance, 234-236
in hyponatremia, 270
in nephrotic edema, 265, 266
physiology and pathophysiology of, 232
regulation of abundance of, 233-234
vasopressin regulation of aquaporin-2 trafficking, 232-233
Aquaporin-3 (AQP-3), 231, 234, 265, 266
Aquaporin-4 (AQP-4), 231, 234, 265, 266, 306
Aquaporin-6 (AQP-6), 231, 365
Aquaporin-7, -10, and -12 (AQP7; AQP10; AQP12), 234
Aquaporin-8 (AQP-8), 234, 265, 266
Aquaporin-9 (AQP-9), 265, 266
ARF, *see* Acute renal failure
L-Arginine, 142
Arginine-vasopressin, *see* Vasopressin
Arrhythmia(s)
in heart failure with edema, 275-276
see also Arrhythmia(s) in renal disease
Arrhythmia(s) in renal disease, 57-65
atrial flutter and fibrillation as, 59-61
bradyarrhythmias as, 62
in CHF, pacing for, 62-63
PVCs and PACs as, 63-64
supraventricular tachycardias as, 61-62
ventricular, *see* Ventricular arrhythmias
Arterial hypertension, *see* Hypertension
Arterial needle for vascular access to HD, 473
Arteriovenous fistula (AVF) in pediatric HD, 472, 473
Arteriovenous ultrafiltration, continuous, for edema of heart failure, 279-280
Ascites, *see* Ascites in cirrhosis; Congestive heart failure with cirrhosis, Na and water retention in

Ascites in cirrhosis, 308-316
pathology of, 308-311
practical approach to patients with, 314-316
preascitic stage of cirrhosis, Na retention in, 317-322
theories on formation of, 311
therapy and management of, 311-314
Ascorbic acid (vitamin C), 187, 225
Aspirin
for CV disease in renal disease, 20-22, 25, 28-30, 32, 33, 60
in preeclampsia, 186
in renal disease progression, 593
Assessment
of extracellular fluid volume in HTN of ESRD, 151-152
of pediatric CPD outcome, 484
renal transplant candidate, for coronary revascularization, 48-49
see also Assessment of dRTA; Diagnosis; Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of *and specific conditions*
Assessment of dRTA, 95-96, 102-105
of hyperkalemic dRTA, 104-105
of hypokalemic dRTA, 102-103
Associated conditions
with cyclic idiopathic edema, 244
with normal anion gap hyperchloremic metabolic acidosis, 95
see also Cardiovascular disease with renal disease; Morbidity *and specific conditions*
AT_1 receptor(s) of ANG II
ANG II actions mediated by, renal disease progression and, 536-537
functional genomics of, and RAS pathophysiology, 584
functions of, 536
and genetic RAS variability, 584, 587
in glomerular injury, 544, 551
hemodynamic-independent ANG II effects and, 570
intrarenal RAS protection, 598
in tubulointerstitial injury, 544, 551
see also AT_1 receptor antagonists
AT_1 receptor antagonists
ANG (1-7) and, 540
in fibrotic diseases, 563
in glomerular injury, 547, 550-552
intrarenal RAS protection and, 600
protective effects of, on intrarenal RAS, 600
response to therapy with, 586
in tubulointerstitial injury, 554, 558, 559
in UTO, 141, 142
see also Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases
AT_2 receptor(s) of ANG II
ANG II actions mediated by, renal disease progression and, 537-539
in glomerular injury, 544, 551
see also AT_2 receptor antagonists
AT_2 receptor antagonists
aldosterone and, 573
see also Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases
Atenolol, 19, 60, 70, 73
Atheroembolic disease, percutaneous coronary intervention-related, 44-45
ATPase, *see* H-ATPase; H,K-ATPase; Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and
Atrial contractions, premature, 63-64
Atrial flutter and fibrillation, 59-61
Atrial natriuretic factors (proANPs), adsorption of, in uremia, 298-302
clinical importance of proANPs, 299
in HD patients, *see* Hemodialysis for edema, proANPs and
proANPs in ANP family, 298-299
Atrial natriuretic peptide(s) (ANPs)
in CHF with cirrhosis, 165
proANPs in family of, 298-299; *see also* Atrial natriuretic factors, adsorption of, in uremia
role of, in cyclic idiopathic edema, 246
see also Urodilatin, role of, in fluid regulation
α (alpha) Atrial natriuretic peptide(s) (ANPs), HD effects on, 300, 301
Atropine, 53, 55
Autosomal dominant polycystic kidney disease (ADPKD), 107-123
cell proliferation in, 113-115
cyst growth and extracellular matrix remodeling in, 116-117
cyst pathogenesis in, 113
genetics of, *see* Mutations of *PKD1* and *PKD2* genes in ADPKD; Polycystin-1 in ADPKD; Polycystin-2 in ADPKD
transepithelial fluid secretion in, 115-116
see also Pediatric autosomal dominant polycystic kidney disease, preventing progression of
AVF (arteriovenous fistula) in pediatric HD, 472, 473
AVP (arginine-vasopressin), *see* Vasopressin
Azathioprine
for FSGS, 337, 339
in pediatric renal transplantation, 512-514, 516, 523
in renal transplantation, 182, 213, 215
Azithromycin, 523

Bacterial infections, pediatric postrenal transplantation, 523
Basiliximab, 215, 514, 517
Basolateral Na,K-ATPase, *see* Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and
BBB (blood-brain barrier) in vasogenic cerebral edema, 303-305
Belgian studies of rGH effects on adult height of dialyzed ESRD children, 491
Beliefs of Mottep study participants on organ donation, 425
Benazepril, 70, 431
Beneficial effects
of ACE inhibitors on renal function, 73
see also Clinical effects of rHuEPO therapy in dialyzed ESRD children and in CRI children; Coronary revascularization in renal transplant candidates, risk and benefit of
"Benign" hypertensive nephrosclerosis, 334-335
Bepridil, 389
Bepridine, 389
Beta-adrenergic receptor antagonists, *see* β-Adrenergic receptor antagonists

Beta (β)-hydroxy-β-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), 20, 130, 351, 434-435
Beta$_1$-integrins, *see* Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of
BIA (bioelectrical impedance analysis) in heart transplantation, 282-285
Bicarbonate, *see* HCO_3; HCO_3/Cl exchanger
Biochemical events, functions of cytokines and, in diabetic nephropathy, 126-127
Bioelectrical impedance analysis (BIA) in heart transplantation, 282-285
Biologic interactions between TGF-β and AT_2 receptor antagonists, fibrotic diseases and, 563-564
Biophysics of BBB opening in vasogenic cerebral edema, 304
Bisoprolol, 162
Black nephrologists, absence of, on inner city neighborhood hospital staff, 330-331
Black population, *see* Urban renal disease
Blood-brain barrier (BBB) in vasogenic cerebral edema, 303-305
Blood circulation, extracorporeal, and HD vascular access, 473-474
Blood glucose, control of, in diabetic nephropathy, 129
Blood pressure (BP)
  in CAD, 18-20
  see also Ambulatory blood pressure monitoring; Hypertension; Hypotension
Blood purification
  theoretical and practical bases of, 471-472
  see also Dialysis
Blood volume
  effective arterial, in nephritic edema, 257-261
  see also entries beginning with terms: Dry body weight
BMI (body mass index), as index of nutritional status of children on CPD, 485
BMP-7 (bone morphogenetic protein-7) osteogenic protein-1, 142
Body compartments in cyclic idiopathic edema
  pathogenesis of fluid distribution in, 244-245
  two-compartment lymphoscintigraphy of, 248-249
Body fluid, *see* Blood volume; Fluid
Body mass index (BMI), as index of nutritional status of children on CPD, 485
Body water
  total, in pregnancy, 178-179
  see also Congestive heart failure with cirrhosis, Na and water retention in; Edema; Fluid
Body weight, *see* Dry body weight
Bone disease, *see* Pediatric renal osteodystrophy with CRI and ESRD
Bone morphogenetic protein-7 (BMP-7; osteogenic protein-1) for UTO, 142
Bosentan, 273
BP, *see* Blood pressure
Bradyarrhythmias, 62
Brain
  rHuEPO therapy effects on, 194
  see also Cerebral edema
Bretylium, 58, 70
Bromocriptine, 246, 249
Bumetanide, 69
Burn injury, edema and
  in ARF, 253-254
  P_{if} in, 223-224
Bypass surgery, *see* Coronary artery bypass graft for coronary syndrome in renal disease

CABG, *see* Coronary artery bypass graft for coronary syndrome in renal disease
CAD, *see* Coronary artery bypass graft for coronary syndrome in renal disease; Coronary artery disease in renal disease; Coronary revascularization in renal transplant candidates, risk and benefit of; Percutaneous coronary angiography and/or angioplasty, renal implications of
Calcifediol, 445
Calcimimetics, 448
Calcineurin inhibitors, 510-511, 516, 517
  see also Cyclosporine; FK506
Calcitriol, 342, 445-447
  altered synthesis of, and secondary hyperparathyroidism in pediatric renal osteodystrophy, 441-442
Calcium, 7, 69, 186, 447, 466
Calcium channel blockers (CCBs), 163, 216
  for CV disease in renal disease, 19, 21, 41, 60, 62, 69, 75
  in cyclic idiopathic edema, 247
  drug interactions with, 387-389
  effects of, on AQP-2, 235
  for HTN of pediatric ADPKD, 431
  for Na and water retention in heart failure with cirrhosis, 163
  in renal transplantation, 216
  see also specific calcium channel blockers
Calmodulin, 510
CAN (chronic allograft nephropathy), 215-216
Candesartan, 69, 569, 596-598
Capsaicin, 225
Captopril
  for CV disease in renal disease, 9, 70, 73, 75
  for cyclic idiopathic edema, 247
  for diabetic nephropathy, 128, 129
  progression of renal disease and, 558, 569, 574, 597, 598
Cardiac drugs, *see entries beginning with terms*: Cardiovascular drugs
Cardiac enzymes in acute coronary syndrome, 26-27
Cardiac failure, *see* Heart failure, edema and; Heart failure in renal disease *and entries beginning with terms*: Congestive heart failure
Cardiac fibrosis, hemodynamic-independent effects of ANG II receptor antagonists in, 565-570
Cardiac procedures
  rHuEPO effects on, in dialyzed ESRD children and in CRI children, 453
  for urban renal disease patients, factors influencing access to, 367-376
  see also Coronary artery bypass graft for coronary syndrome in renal disease; Coronary revascularization in renal transplant candidates, risk and benefit of; Percutaneous coronary angiography and/or angioplasty, renal implications of
Cardiovascular (CV) disease with renal disease
  introduction to, 1-2
  rHuEPO therapy effects on, 194-195
  see also Acute coronary syndrome in renal disease; Arrhythmia(s) in renal disease; Coronary artery disease in renal

disease; Coronary revascularization in renal transplant candidates, risk and benefit of; Heart failure in renal disease; Percutaneous coronary angiography and/or angioplasty, renal implications of; Pericardial disease in renal disease *entries beginning with terms*: Cardiovascular drugs *and specific drugs*
Cardiovascular (CV) drugs, pharmacology of, in renal disease, 66-78
dosing of, for dialyzed patients, 69-71
effects of renal dysfunction on, 66-69
interactions with, 68-69, 71, 387
special considerations on, *see* Cardiovascular drugs in renal disease, special considerations on pharmacology of
see also Drug therapy of CV disease in renal disease
Cardiovascular (CV) drugs in renal disease, special considerations on pharmacology of, 71-75
on ACE inhibitors, 73-74
on angiotensin II receptor antagonists, 74-75
on calcium channel blockers, 75
on digitalis aminoglycosides, 71-73
on diuretics, 71
Cardioverter-defibrillator, implantable, 58-59
Carvedilol, 68, 162, 594
Catheter-based technology(ies)
radiofrequency catheter ablation for arrhythmias, 61, 62
see also Percutaneous coronary angiography and/or angioplasty, renal implications of
CAVV (continuous arteriovenous ultrafiltration) for edema of heart failure, 279-280
CCBs, *see* Calcium channel blockers
Cellular proliferation
in ADPKD, 113-115
in tubulointerstitial injury, 559-560
Cephalosporins, 524
Cerebral edema, 303-307
cytotoxic, 305-306
due to osmotic gradients, 306
interstitial, 306
therapy of, 306
vasogenic, 303-305
cGMP (cyclic guanosine monophosphate), HD effects on, 300, 301
Charity, *see* Dialysis for urban ESRD patients in Singapore, funding of, through charity
CHF, *see entries beginning with terms*: Congestive heart failure
Children, *see entries beginning with term*: Pediatric
Chlorambucil, 337, 338
Chloride, *see* Cl/HCO_3 exchanger; $Na^+.Cl^-$ cotransporter; $Na^+.K^+.2Cl^-$ cotransporter
Chlormethiazole, 187
Choice
of contrast agents for percutaneous coronary intervention, 36-37
of therapies at Vicenza dialysis center, 348-349
Chronic allograft nephropathy (CAN), 215-216
Chronic hypertension (HTN) in pregnancy, 184
with superimposed preeclampsia, 183
Chronic peritoneal dialysis, *see* Adequacy of pediatric CPD for ESRD
Chronic rejection of pediatric renal transplantation, 500-501, 504-506
Chronic renal disease (chronic renal failure), *see* Dialysis; Hypertension in ESRD; Pediatric chronic renal insufficiency and ESRD; Renal transplantation *and entries beginning with acronym*: rHuEPO
Chronic renal insufficiency, *see* Pediatric chronic renal insufficiency and ESRD
Chronic renal parenchymal disorders, hypertensive pregnancy with, 179-181
Cidofovir, 386, 388, 391
Cigarette smoking, urban renal disease and, 362
Cilapazil, 431, 432
Cimetidine, 68
Circulating atrial natriuretic factors (proANPs), dialyzer membrane effects on, 300-301
Circulation, extracorporeal, and vascular access for HD, 472-474
CIRF, *see* Contrast induced renal failure
Cirrhosis, edema with, 308-322
congestive heart failure with, *see* Congestive heart failure with cirrhosis, Na and water retention in
lithium clearance in, and tubular Na reabsorption, 323-326
preascitic stage of cirrhosis, Na retention in, 317-322; *see also* Ascites in cirrhosis
V_2 receptor antagonists in hyponatremia of, *see* V_2 receptor agonists and V_2 receptor antagonists
Cisplatin, 235
Cl (chloride), *see* Cl/HCO_3 exchanger; $Na^+.Cl^-$ cotransporter; $Na^+.K^+.2Cl^-$ cotransporter
Clarithromycin, 523
Classification of hypertensive disorders of pregnancy, 183-184
Cl/HCO_3 (chloride/bicarbonate) exchanger in hypokalemic dRTA, 101-102
Clinical assessment, *see* Assessment
Clinical effects of rHuEPO therapy, 194-196
adverse, 198
see also Clinical effects of rHuEPO therapy in dialyzed ESRD children and in CRI children
Clinical effects of rHuEPO therapy in dialyzed ESRD children and in CRI children
adverse, 456-457
on cardiac performance and, 453
on cognition and, 454
on exercise capacity and, 453
on growth, 466
on hematocrit and, *see* rHuEPO therapy for anemia in dialyzed ESRD children and in CRI children, hematocrit and
on quality of life, 454
Clinical factors
affecting urban renal disease patients' access to cardiac procedures, 369-370
see also specific clinical factors
Clinical features
of cyclic idiopathic edema, 244
of HIVAN, 394, 395
see also Clinical features of CV disease in renal disease *and specific conditions*
Clinical features of CV disease in renal disease
of acute coronary syndrome, 25-26
of atheroembolic renal disease, 44
of pericardial disease, 52-53

see also Symptoms of CV disease in renal disease *and specific conditions*
Clinical genetics of RAS in renal disease, 584-588
and initiation of nondiabetic and diabetic renal disease, 585-586
and renal function loss progression, 586
response to therapy and, 586-588
Clinical importance of pro-ANPs, 299
Clinical spectrum of hyperkalemic dRTA, 96
Clinical trial of VPA-985 in hyponatremia of cirrhosis, 271
Clofibrate, 20
Clonidine, 19, 69, 247, 336
Clotting, vascular access, due to rHuEPO, 196
CMV (cytomegalovirus) infections, postrenal transplantation, in children, 523-525
Cocaine use, role, in urban renal disease, 336, 357, 362-366
Coenzyme A reductase inhibitors, HMG-, 20, 130, 351, 434-435
Cognition, rHuEPO effects on, 194
in ESRD children and in CRI children, 454
Collapse index, defined, 475
Colloid osmotic pressure (COP) in nephrotic edema, 267
Comorbidity, *see* Associated conditions
Complex renal disease processes, genetic variability of RAS and, 580-582
Complications, *see* Adverse effects
Computed tomography (CT), electron-beam, of CAD, 18
Congestive heart failure, *see* Congestive heart failure with cirrhosis, Na and water retention in; Congestive heart failure in renal disease
Congestive heart failure (CHF) with cirrhosis, Na and water retention in, 157-172
pathology of, *see* Pathology of CHF; Pathology of cirrhosis
therapy and management, 150, 162-163, 167-168
unifying hypothesis of fluid volume regulation in, 158-159
Congestive heart failure (CHF) in renal disease
in ARF, edema and, 253
arrhythmias and, 57, 58, 60, 62-63
CAD and, 13, 14, 17, 19
percutaneous coronary interventions and, 36, 41, 45
pericardial disease and, 53
Contaminants, water, in HD, complications associated with, 471
Continuous arteriovenous ultrafiltration (CAVU) for edema of heart failure, 279-280
Continuous plasma volume measurement in HD patients, 288-289
Continuous venovenous ultrafiltration (CVVU) for edema of heart failure, 279-280
Contrast agents for percutaneous coronary interventions in renal disease, 36-43
choice of, 36-37
CIRF due to, *see* Contrast induced renal failure
volume of, 37-38
Contrast induced renal failure (CIRF), 31, 38-43
diagnosis and incidence of, 39
morbidity and mortality due to, 38-39
pathogenesis of, 40-41
prevention of, 41-43
risk factors for, 39-40
Convection
blood purification on HD by, 472
Na removal by, dry body weight and, 292-293
COP (colloid osmotic pressure) in nephrotic edema, 267
Coronary angiography and/or angioplasty, *see* Percutaneous coronary angiography and/or angioplasty, renal implications of
Coronary artery bypass graft (CABG) for coronary syndrome in renal disease, 21, 22
for acute coronary syndrome, 31, 36-38
Coronary artery disease, *see* Coronary artery bypass graft for coronary syndrome in renal disease; Coronary artery disease in renal disease; Percutaneous coronary angiography and/or angioplasty, renal implications of
Coronary artery disease (CAD) in renal disease, 13-24
arrhythmias and, 57
heart failure and, 3-7
invasive testing for, 18-19
management of, 19-21
noninvasive testing for, *see* Noninvasive diagnosis of CAD in renal disease
see also Acute coronary syndrome in renal disease; Coronary artery bypass graft for coronary syndrome in renal disease; Coronary revascularization in renal transplant candidates, risk and benefit of
Coronary revascularization, *see* Coronary artery bypass graft for coronary syndrome in renal disease; Coronary revascularization in renal transplant candidates, risk and benefit of; Percutaneous coronary angiography and/or angioplasty, renal implications of
Coronary revascularization in renal transplant candidates, risk and benefit of, 47-51
in diabetic candidates, 47-50
historical perspective on, and demographics of transplant recipients, 47-48
Coronary risk factors for acute coronary syndrome in renal disease, 25
Coronary syndrome, *see* Acute coronary syndrome in renal disease
Corticosteroids, *see* Steroids
Corticotropin-releasing hormone (CRH), 225
Cost of ESRD care, *see* Dialysis for urban ESRD patients in Singapore, funding of, through charity *and entries beginning with term*: Medicare
Costimulatory molecules, immunosuppression with, 514-515
Cotrimoxazole, 523, 524, 527
CPD (chronic peritoneal dialysis), *see* Adequacy of pediatric CPD for ESRD
Crack cocaine, *see* Cocaine use
CRD and CRF (chronic renal disease; chronic renal failure), *see* Dialysis; Hypertension in ESRD; Pediatric chronic renal insufficiency and ESRD; Renal transplantation *and entries beginning with acronym*: rHuEPO
CRH (corticotropin-releasing hormone), 225
Critical care at Vicenza dialysis center, 352-353
CsA, *see* Cyclosporine
CT (computed tomography), electron-beam, of CAD, 18
CTL molecules, correlation between acute rejection of pediatric renal transplantation and, 503
CV disease, *see* Cardiovascular disease with renal disease
CVVU (continuous venovenous ultrafiltration) for edema of heart failure, 279-280

Cyclic guanosine monophosphate (cGMP), HD effects on, 300, 301
Cyclic idiopathic edema, 244-250
  body compartments in, *see* Body compartments in cyclic idiopathic edema
  clinical features of, and disorders associated with, 244
  defined, 244
  diagnosis of, 244, 245, 248-249
  hormonal role in, *see* Cyclic idiopathic edema, hormone(s) in
  therapy of, 246, 249
Cyclic idiopathic edema, hormone(s) in, 245-247
  AVP, 246; *see also* Vasopressin
  luteinizing hormone in hypothalamic disorders, 245
  renin-angiotensin II-aldosterone axis, 246-247
  thyroxine and ANPs, 246
Cyclophilins, 510
Cyclophosphamide, 266, 337-339, 406, 512
Cyclosporine (CsA)
  CCB effects on, 75
  drug interactions with, 68, 69
  for nephrotic edema, 266
  pregnancy and, 181-182
  in renal transplantation, *see* Cyclosporine in renal transplantation
  for urban patients with FSGS, 337, 338
Cyclosporine (CsA) in renal transplantation, 213-218
  pediatric transplantation, 508, 510-512, 514-517, 522-523
Cyst, *see* Autosomal dominant polycystic kidney disease *and entries beginning with term*: Cystic
Cystic activating factor, 437
Cystic phenotype of PKD epithelium, therapies targeting, in prevention of ADPKD, 435-437
Cytokines
  biochemical events and functions of, in diabetic nephropathy, 126-127
  in heart failure, 274
  role of, in pediatric renal transplantation rejection, 498-501, 504-506
  see also specific cytokines
Cytomegalovirus (CMV) infections, postrenal transplantation, in children, 523-525
Cytotoxic cerebral edema, 305-306

Daclizumab, 215, 514, 517
Dalteparin, 29
Defibrillator, implantable cardioverter-, 58-59
Delivery of health care in Singapore, 411-413
Delvirdine, 388
Demographics
  of renal transplant candidates having undergone coronary revascularization, 47-48
  see also Demographics of urban renal disease patients *and specific conditions*
Demographics of urban renal disease patients
  and access to cardiac procedures, 369-370
  with HIVAN, 398-400
  income disparities and, 379, 380
  of Mottep study respondents, 423-424
Development, *see* Growth and development
Dextran, 225, 227, 313
Diabetes insipidus (DI), aquaporin-2 in, 234-236
  acquired neurogenic, 234-236
  inherited, 234
Diabetes mellitus, *see* Diabetes mellitus, and CV disease in renal disease; Diabetes mellitus in urban renal disease; Diabetic nephropathy
Diabetes mellitus (DM), and CV disease in renal disease
  ACE inhibitor effects on, 74
  acute coronary syndrome, 25
  coronary artery disease, 13, 19, 20, 22
  coronary revascularization in renal transplant candidates with, 47-50
  heart failure, 4-6, 8, 9
  percutaneous coronary interventions and, 39-41, 43, 45
  and pharmacology of CV drugs, 74, 75
Diabetes mellitus (DM) in urban renal disease, 329, 330, 362, 370
  glomerular disease, 404
  and outcome, 380, 381
  in Singapore, 414, 416
Diabetic nephropathy, 124-132
  genetics of, 125-126
  hypertension and, 74, 126-129, 131
  interactions between biochemical events and cytokines in, 126-127
  management of, *see* Therapy and management of diabetic nephropathy
  renal hemodynamics in, *see* Diabetic nephropathy, renal hemodynamics in
  see also Genetic variability of RAS in diabetic and nondiabetic renal disease
Diabetic nephropathy, renal hemodynamics in
  alterations in renal hemodynamics, 127
  RAS and, 597-598
Diagnosis
  of cyclic idiopathic edema, 244, 245, 248-249
  of hepatorenal syndrome, 310
  of pediatric renal transplantation rejection, 501, 504-505
  of preeclampsia, 183-184
  of refractory ascites, 315
  see also Assessment; Diagnosis of CV disease in renal disease; Diagnosis of pediatric renal transplantation; Evaluation *specific conditions and specific diagnostic procedures*
Diagnosis of CV disease in renal disease
  acute coronary syndrome, 25-28
  of arrhythmias, 58
  of CIRF, 39
  and coronary artery disease, *see* Invasive testing for CAD in ESRD; Noninvasive diagnosis of CAD in renal disease
  of uremic pericarditis, 53
  see also Noninvasive diagnosis of CV disease in renal disease
Diagnosis of pediatric renal transplantation
  chronic rejection, 504-505
  and postrenal transplantation evaluation, 528
Dialysate used in pediatric HD, 471, 474-475
Dialysis, 204-212
  adequacy of, *see* Adequacy of dialysis
  anaphylactoid reactions on, 74-75
  CV drug dose for patients on, 69-71
  dose of, *see* Dose, dialysis
  funding for, *see* Dialysis for urban ESRD patients in Singa-

pore, funding of, through charity *and entries beginning with term*: Medicare
intoxication on, due to trace elements, 207-210
pediatric, *see* Adequacy of pediatric CPD for ESRD; Growth retardation of dialyzed ESRD children; Hemodialysis for pediatric ESRD; rGH therapy of dialyzed ESRD children; rHuEPO therapy for anemia in dialyzed ESRD children and in CRI children
see also Cardiovascular disease with renal disease; Dialysis centers; Hemodialysis; Peritoneal dialysis; rHuEPO therapy for anemia of ESRD
Dialysis centers
equipment needed in, for pediatric HD, 470-471
see also Dialysis centers, inner city
Dialysis centers, inner city
effects of quality of care in, on patient outcome, 356-361
patient survival and, 359-360
see also Dialysis for urban ESRD patients in Singapore, funding of, through charity; Dialysis for urban ESRD patients at Vicenza center
Dialysis membranes, HD, parameters of, 476
Dialysis pericarditis, 54-55
Dialysis session
duration of, at Vicenza dialysis center, 349-350
monitoring pediatric HD session, 476-477
Dialysis for urban ESRD patients in Singapore, funding of, through charity, 411-418
health care delivery system in Singapore, 411-413
mortality rates and, 416
outcome of, *see* Outcome, intermediate HD, in Singapore
rehabilitation outcomes and, 416-417
role of NFK-S in, 413-414
Dialysis for urban ESRD patients at Vicenza (Italy) center, 346-355
adequacy of, 350-352
dose and treatment schedules of, 349-350
in need of critical care, 352-353
pre-ESRD care and initiation of, 347
research pursued at, 353
structure of, and population served by, 346-347
treatment options and integration of therapies at, 348-349
vascular and peritoneal access methods used at, 348
Dialyzer membrane, 300-302
effects of, on circulating proANPs, 300-301
proANP adsorption by, 301-302
Diazepam, 187
Diazoxide, 247
Didanosine, 388
Dietary therapy
for HTN and proteinuria in pediatric ADPKD, 431
of nephrotic edema, 262, 263
for preventing pediatric ADPKD progression, 431-435
protein restriction as, *see* Protein restriction
with supplementation for growth-retarded ESRD children, 447, 464, 466
at Vicenza dialysis center, 351
see also specific conditions
Diffusion
blood purification on HD by, 472
Na removal by, dry body weight and, 293-294
Digitalis aminoglycosides, 259
see also Digitoxin; Digoxin
Digitoxin, 73
Digoxin, 8-10, 60, 61, 67-73, 389
Dihydrotachysterol, 445, 447
Diltiazem, 60, 61, 69, 75, 163, 388, 389
Dilutional hyponatremia with cirrhosis, practical approach to patients with, 315-316
Dipivoxil, 388
Dipyridamole scintigraphy, 15, 16, 22, 26
Disopyramide, 58, 70, 389
Distal Na (sodium) delivery in hyperkalemic dRTA, 98-99
Distal nephron
intraluminal RAS in, 600
tightness of, in hypokalemic dRTA, 102
Distal renal tubular acidosis (dRTA), 94-106
altered or absent H-ATPase in, 99-100
assessment of, *see* Assessment of dRTA
defective basolateral Na,K-ATPase and hyperkalemic, *see* Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and
hypokalemic, *see* Hypokalemic distal renal tubular acidosis
mechanisms responsible for, 94-95
Distribution, drug, in renal disease, 67
Diuretics
for ascites in cirrhosis, 312, 314-315
for CV disease in renal disease, 8, 40, 41, 68, 70, 71, 73-74
for edema, 245, 247-249, 252, 255, 266, 278, 280
for HTN of pediatric ADPKD, 431
for Na and water retention in CHF with cirrhosis, 157, 162
for urban renal disease patients, 336
see also specific diuretics
DM (diabetes mellitus), *see* Diabetes mellitus, and CV disease in renal disease; Diabetes mellitus in urban renal disease; Diabetic nephropathy
Dobutamine, 163
see also Dobutamine stress echocardiography of CV disease in renal disease
Dobutamine stress echocardiography (DSE) of CV disease in renal disease
for acute coronary syndrome, 26
for CAD, 15, 17, 22, 48-49
Dofetilide, 58
Donations, organ, *see* Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of
Dopamine, 42
Dose
contrast agent, 37
rHuEPO, 193
see also Dose, CV drug, in renal disease; Dose, dialysis *and specific drugs*
Dose, CV drug, in renal disease
with acute coronary syndrome, 30-33
CAD, 19
for dialyzed patients, 69-71
Dose, dialysis
dialysis adequacy and, 204-207, 480-481
HD, intermediate HD outcomes in U.S. and Singapore, compared, 415
in pediatric CPD for ESRD, 480-481
at Vicenza dialysis center, 349-350

Doxazosin, 69, 162, 389
dRTA, *see* Distal renal tubular acidosis
Drug absorption, renal dysfunction effects on, 66-67
Drug abuse, role of, in urban renal disease
  alcohol, analgesics, NSAIDs, and cigarettes, 362
  and role of cocaine in HIVAN, 336, 337, 362-366
Drug distribution, renal dysfunction effects on, 67
Drug excretion, renal dysfunction effects on, 67-69
Drug interactions
  between antiretroviral medications and antihypertensive drugs, 387-390
  between CV and renal drugs, 68-69, 71, 75
Drug metabolism, renal dysfunction effects on, 67
Drug resistance, *see* Resistance
Drug therapy, *see* Drug therapy of CV disease in renal disease; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients *entries beginning with terms*: Cardiovascular drugs *specific drugs and specific conditions*
Drug therapy of CV disease in renal disease, 28-30
  of acute MI with ST segment elevation, 28-29
  of arrhythmias, 58, 60-61
  of CAD, 19-21
  of heart failure, 8-10
  of unstable angina and non-Q wave MI, 29-30
  see also Cardiovascular drugs, pharmacology of, in renal disease *and specific drugs*
Dry body weight
  postdialytic adjustment of, in pediatric HD, 474-475
  see also Dry body weight of edema patients of HD
Dry body weight, Na balance and, 291-297
  measurement of dry body weight, 291-292
  and Na removal, 292-295
Dry body weight of edema patients on HD, 286-297
  continuous plasma volume measurement and, 288-289
  hemodynamic instability and, 287
  hypertension and, 286-288, 292, 293
  measurement of, 287-288
  Na balance and, *see* Dry body weight, Na balance and
DSE, *see* Dobutamine stress echocardiography of CV disease in renal disease
Dutch studies of rGH effects on dialyzed ESRD children adult height, 490-491

EABV (effective arterial blood volume) in nephritic edema, 257-261
EBCT (electron-beam computed tomography) of CAD in renal disease, 18, 22
EBV (Epstein-Barr) infections, postrenal transplantation, in children, 525
ECF, *see* Extracellular fluid volume
ECG, *see* Electrocardiogram of renal disease patients
Echocardiography of CAD in renal disease, 14-19
  intravascular, 18-19
  stress, 14-17
Echocardiography of CV disease in renal disease
  for coronary revascularization in renal transplant candidates, 48
  of heart failure, 3, 6-8
  of uremic pericarditis, 53
  see also Echocardiography of CAD in renal disease
Eclampsia, *see* Preeclampsia-eclampsia
ECM, *see* Extracellular matrix
Edema
  introduction to, 221
  see also Acute renal failure, edema with; Aquaporin(s); Atrial natriuretic factors, adsorption of, in uremia; Atrial natriuretic peptide(s); Bioelectrical impedance analysis; Cerebral edema; Congestive heart failure with cirrhosis, Na and water retention in; Cyclic idiopathic edema; Hemodialysis for edema; Hyponatremia, edema and; Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of; Nephritic edema; Nephrotic edema
Education
  changes in perceptions of Mottep study participants based on level of, 426, 427
  patient, *see* Patient education and information
Efavirenz, 388
Effective arterial blood volume (EABV) in nephritis edema, 257-261
EGF, *see* Epidermal growth factor
Eicosapentaenoic acid, 186
EKI-785, 436
Electrocardiogram (ECG) of renal disease patients
  with acute coronary syndrome, 25-28
  with arrhythmias, 58, 61
  with CAD, 13-15, 17
  for coronary revascularization in renal transplant candidates, 48
  with pericardial disease, 53, 55, 56
Electrolyte imbalance, *see* Cirrhosis, edema with
Electron-beam computed tomography (EBCT) of CAD in ESRD, 18, 22
ENaC, *see* Epithelial Na channel, genetic disorders of
Enalapril
  in CV disease with renal disease, 70
  in diabetic nephropathy, 142
  for HTN of pediatric ADPKD, 431, 432
  progression of renal disease and, 565, 570, 594, 596
  for urban renal disease patients, 341
  in UTO, 142
Encainamide, 389
Endogenous erythropoietin (EPO), physiology of, 190-192
Endothelial function
  in ESRD with HTN, 150
  in heart failure, 276
Endothelin in heart failure, 273-274, 277
End-stage renal disease, *see* Dialysis; Hypertension in ESRD; Pediatric chronic renal insufficiency and ESRD; Renal transplantation *and entries beginning with acronym*: rHuEPO
Enoxaparin, 29
Ephedrine, 249
Epidemiology
  of HTN in ESRD, 146-148
  see also Epidemiology of urban HIVAN; Incidence; Prevalence *and specific conditions*
Epidemiology of urban HIVAN, 395-400
  demographics, 398-400
  incidence and prevalence, 395-398
Epidermal growth factor (EGF)
  in ADPKD, 436

in PKD, 114
in UTO, 140
Epithelial Na channel (ENaC), genetic disorders of, 85-89
in essential hypertension, 88-89
functional studies of, 86
in PHA-1, 87-88
in pseudoaldosteronism, 86-87
Epithelium, cystic phenotype of PKD, therapies targeting, in prevention of ADPKD, 435-437
EPO, *see* Erythropoietin
Eprosartan, 598
Epstein-Barr virus (EBV) infection, postrenal transplantation, in children, 525
Eptifibatide, 30-32
Equipment needed for pediatric dialysis management center, 470-471
Erythromycin, 523
Erythropoiesis, physiology of, 191-192
Erythropoietin (EPO)
endogenous, physiology of, 190-192
see also entries beginning with acronym: rHuEPO
Esmolol, 28, 69
ESRD, *see* Dialysis; Hypertension in ESRD; Pediatric chronic renal insufficiency and ESRD; Renal transplantation *and entries beginning with acronym*: rHuEPO
Essential hypertension (HTN), genetic disorders of ENaC in, 88-89
Estrogen in cyclic idiopathic edema, 247
Etiology
of preeclampsia, 184-185
see also specific conditions
Evaluation
post-pediatric renal transplantation, 528
pro-ANP, in HD, 300, 301
see also Assessment; Diagnosis
Excretion, drug, renal dysfunction effects on, 67-69
Exercise capacity, rHuEPO effects on, in CRI children and in dialyzed ESRD children, 453
Exercise protocols in noninvasive testing, 14-16
for acute coronary syndrome, 26
for CAD, 14-16
Extracellular fluid (ECF) volume
expanded, aquaporin-2 in, 236
in HTN of ESRD, 149-152
Extracellular matrix (ECM)
in GS, synthesis and degradation of, 548-549
remodeling of, in ADPKD, 116-117
Extracorporeal blood circulation, and vascular access for HD, 472-474

Fab-digoxin complex, 72
Felodipine, 69, 389
Fenoldopam, 43
Fenoprofen, 253
Fever, postrenal transplantation, in children, evaluation of, 528
Fibrillation
atrial, 59-61
ventricular, 58
Fibrosis
profibrotic responses to renal injury, tissue RAS and, 596-597
see also Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases; Tubulointerstitial fibrosis
"Fill" hypotheses of volume changes in pregnancy, 178-179
First acute rejection episode in pediatric renal transplantation
late, outcome of, 504
risk of, 503
Fish oil for prevention of pediatric ADPKD progression, 431, 433-434
FK binding proteins (FKBP), defined, 510
FK506 (tacrolimus)
CV drug interactions with, 69
see also FK506 in renal transplantation
FK506 (tacrolimus) in renal transplantation, 100, 182, 214, 215
pediatric renal transplantation, 508, 510-512, 516, 522-523
Flaxseed for prevention of pediatric ADPKD progression, 431, 433-434
Flecainide, 58, 70, 387, 389
Fluconazole, 523
5-Flucytosine, 524
Fluid
distribution in cyclic idiopathic edema, pathogenesis of, 244-245
regulation of, *see* Urodilatin, role of, in fluid regulation
secretion of transepithelial, in ADPKD, 115-116
see also Congestive heart failure with cirrhosis, Na and water retention in; Edema; Fluid volume; Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of; Transepithelial fluid; Water
Fluid and electrolyte imbalance in cirrhosis, *see* Cirrhosis, edema with
Fluid volume
control of, in pregnancy, 176-178
extracellular, in HTN of ESRD, 149-152
regulation of, in CHF with cirrhosis, unifying hypothesis of, 158-159
ventricular volume overload, 6-7
Fluoroquinolones, 522
Flutter, atrial, in renal disease, 59-61
Focal segmental glomerulosclerosis (FSGS), urban, 336-338, 405-406
Folic acid, 20
Foscarnet, 386, 391
Fosinopril, 69
Free water, and growth retardation in dialyzed ESRD children, 464-465
Frequency, dialysis
of HD, HTN control in ESRD and, 152-153
at Vicenza center, 349-350
FSGS (focal segmental glomerulosclerosis), urban, 336-338, 405-406
Functional genomics of RAS, diabetic and nondiabetic renal disease and, 582-584
Functional studies of ENaC, 86
Funding for ESRD care, *see* Dialysis for urban ESRD patients in Singapore, funding of, through charity *and entries beginning with term*: Medicare
Furosemide
for aldosterone deficiency, 97
for CV disease in renal disease, 41, 42, 67, 69
in edema, 167, 235, 255, 266, 314

Future plans of Mottep study participants' perceptions of, 425, 426

Ganciclovir, 523-525
Gemfibrozil, 20
Gene therapy of pediatric ADPKD, 436
Genetic variability of RAS in diabetic and nondiabetic renal disease, 580-592
  clinical genetics of RAS in disease, *see* Clinical genetics of RAS in renal disease
  in complex disease processes, 580-582
  functional genomics of RAS, 582-584
  and pathophysiology of RAS, 582-584, 588
  quantitative considerations on, 582
Genetics
  of diabetic nephropathy, 125-126
  see also Autosomal dominant polycystic kidney disease; Gene therapy; Genetic variability of RAS in diabetic and nondiabetic renal disease; Inherited diabetes insipidus; Phenotype; Polymorphism; Renal apical Na^+ transporters, genetic disorders of
Gentamicin, 341, 524
German study of rGH effects on adult height of dialyzed ESRD children, 492-493
Gestational hypertension, 183, 184
GFR (glomerular filtration rate), adaptations of, to pregnancy, 173-176
GH (growth hormone), *see* rGH therapy of dialyzed ESRD children
Glomerular disease, *see* Socioeconomic and racial factors in urban glomerular disease
Glomerular filtration rate (GFR), adaptations of, to pregnancy, 173-176
Glomerular hypertrophy, GS and, 545-546
Glomerular injury, *see* Angiotensin II in GS *and specific conditions*
Glomerulonephritis (GN), ARF with edema in, 252-253
Glomerulosclerosis (GS)
  urban focal segmental, 336-338, 405-406
  see also Angiotensin II in GS
Glucocorticoid(s), *see* Steroids
Glucocorticoid responsive elements (GRE), defined, 508
Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors for acute coronary syndrome in renal disease, 25, 28, 30, 32
Glycosaminoglycans, 225
GMP (guanosine monophosphate), cyclic, HD effects on, 300, 301
GN (glomerulonephritis), ARF with edema in, 252-253
God's will, liver disease viewed by Mottep study participants as, 425, 426
Gp IIb/IIIa, (glycoprotein IIb/IIIa inhibitors), 25, 28, 30, 32
GRE (glucocorticoid responsive elements), defined, 508
Growth and development
  cyst, in ADPKD, 116-117
  renal, ANG II role in, 539
  statural, of children on CPD, as index of nutritional status, 486-487
  see also Growth retardation of dialyzed ESRD children; rGH therapy of dialyzed ESRD children
Growth hormone, *see* rGH therapy of dialyzed ESRD children
Growth retardation of dialyzed ESRD children, 455, 463-469
  factors associated with, 464-465
  growth optimization strategies for, 466-467
  outcome associated with, 467-468
  prevalence of, 464
  rHuEPO effects on, 455
  see also rGH therapy of dialyzed ESRD children, effects of, on adult height
GS, *see* Glomerulosclerosis
Guanosine monophosphate (GMP), cyclic, HD effects on, 300, 301
Guidelines and recommendations
  on adequacy of pediatric CPD for ESRD, 480
  on frequency of solute clearance measurements, 481-482
  for performing percutaneous angiography and/or angioplasty in patients on metformin therapy, 43-44

HAART (highly active antiretroviral) drugs for HIVAN, 394, 395, 398-401
  H-ATPase (hydrogen-adenosine triphosphatase) in dRTA, 99-100
  HCO_3 (bicarbonate)
  Na, 431, 435
  see also HCO_3/Cl exchanger
HCO_3/Cl (bicarbonate-chloride) exchanger in hypokalemic dRTA, 101-102
HD, *see* Hemodialysis
Health care delivery system in Singapore, 411-413
Health insurance status of urban renal disease patients
  and access to cardiac procedures, 367-376
  effects of, on income-based disparities, 381-382
  see also entries beginning with term: Medicare
Heart failure, *see* Heart failure, edema and; Heart failure in renal disease *and entries beginning with terms*: Congestive heart failure
Heart failure, edema and, 269-281
  HD for, *see* Hemodialysis for edema in heart failure
  pathogenesis of, *see* Pathology of heart failure
  V_2 receptor antagonists in hyponatremia of, 270-271
Heart failure in renal disease, 3-12
  congestive, *see* Congestive heart failure in renal disease
  left ventricular dysfunction and, *see* Left ventricular dysfunction, and heart failure in renal disease
  management of, 7-10
Heart transplantation, BIA in, 282-285
Height, adult, *see* rGH therapy of ESRD children, effects of, on adult height
Hematocrit, *see* rHuEPO therapy for anemia in dialyzed ESRD children and in CRI children, hematocrit and
Hemodialysis (HD)
  dose and adequacy of, and Kt/V, 204-206
  prolonged and/or more frequent, for HTN control in ESRD, 152-153
  see also Cardiovascular disease with renal disease; Dialysis; Hemodialysis for edema; Hemodialysis for pediatric ESRD; Outcome, intermediate HD, in Singapore
Hemodialysis (HD) for edema
  in ARF, 255
  see also Hemodialysis for edema, proANPs and; Hemodialysis for edema in heart failure
Hemodialysis (HD) for edema, proANPs and, 299-301

effects of dialyzer membrane on circulating proANPs, 300-301
and HD effects on α-ANP, cGMP, and proANPs, 300, 301
and membrane adsorption of proANPs, 301-302
proANP evaluation, 299-300
Hemodialysis (HD) for edema in heart failure, 269-281
dry body weight of patients on, *see* Dry body weight of edema patients on HD
HD effects on α-ANP, cGMP, and proANPs, 300, 301
Hemodialysis (HD) for pediatric ESRD, 470-479
adequacy of, 475-477
dialysate for, 471, 474-475
equipment needed for dialysis management center, 470-471
postdialytic dry weight adjustment in, 474-475
prescription and monitoring session of, 476-477
theoretical and practical bases of blood purification, 471-472
vascular access for, 472-474
Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases, 563-572
biologic interactions between TGF-β and, 563-567, 569-571
in cardiac fibrosis, 566-570
in pulmonary fibrosis, 571
in renal fibrosis, 565
Hemodynamic mechanisms, ANG II in GS, 545
Hemodynamics, *see* Blood pressure; Circulation; Diabetic nephropathy, renal hemodynamics in; Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases; Hemodynamic mechanisms; Systemic hemodynamics
Hemofiltration, *see* Hemodialysis for edema in heart failure
Hemoglobin (Hgb), rHuEPO therapy target, 196-197
Heparin, 25, 28-30, 32, 33, 104, 473
Hepatitis virus infections, postrenal transplantation, in children, 526
Hepatorenal syndrome (HRS), 313
diagnosis of, 310
pericardial disease and, 56
Heredity, *see* Genetics
Heroin, role of, in urban renal disease, 337-339, 362, 405
Heroin nephropathy, 338-339, 404
Hgb (hemoglobin), rHuEPO therapy target, 196-197
Highly active antiretroviral (HAART) drugs for HIVAN, 394, 395, 398-401
Hispanic population, *see* Urban renal disease
Histamine-2 antagonists, 67
History of renal transplantation, 47-48, 213-214
HIV-associated nephropathy (HIVAN) in urban population, 334, 387, 394-404
clinical presentation of, 394, 395
epidemiology of, *see* Epidemiology of urban HIVAN
future impact of, 401
patterns of, 338-339
racial and socioeconomic factors of, 403-404
risks for, 395-398
therapeutic approaches to, and patient survival with, 400-401
HIV-1 infection, *see* HIV-associated nephropathy in urban population; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients
HIVAN, *see* HIV-associated nephropathy in urban population
H,K-ATPase (hydrogen,potassium-adenosine triphosphatase), 100-101
HMG-CoA (β-hydroxy-β-methylglutaryl-coenzyme A) reductase inhibitors (statins), 20, 130, 351, 434-435
Hormones, *see* Cyclic idiopathic edema, hormone(s) in *and specific hormones*
Hospital(s), location-based differences in quality of, 331
Hospital staff of inner city hospitals, absence of black nephrologists on, 330-331
Hospitalization
of ESRD children on CPD, 484-485
of ESRD patients on rHuEPO therapy, 195-196
see also specific conditions
HRS, *see* Hepatorenal syndrome
HTN, *see* Hypertension
Human immunodeficiency virus-1 infection, *see* HIV-associated nephropathy in urban population; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients
Hyaluronan, 225
Hydralazine, 9, 69, 247, 336, 388
Hydrocortisone, 53
Hydrogen, *see* H-ATPase; H,K-ATPase; Na^+,H^+ exchanger isoform 3
Hydrostatic pressure, *see* Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of
β (beta)-Hydroxy-β-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), 20, 130, 351, 434-435
Hyperaldosteronism in renal failure, 573-576
Hyperchloremic metabolic acidosis, normal anion gap, conditions associated with, 95; *see also* Distal renal tubular acidosis
Hyperhomocysteinemia, heart failure and CAD in renal disease and, 6, 13
Hyperkalemia
associated with ACE inhibitors, 74
rHuEPO therapy and, 196
see also Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and
Hyperkalemic distal renal tubular acidosis (dRTA), defective basolateral Na,K-ATPase and, 96-99
aldosterone deficiency and, 96-97
amiloride and, 98-99
assessment and therapy of, 104-105
distal Na delivery in, 98-99
pseudohypoaldosteronism and, 97-98
Hyperlipidemia in renal disease
with acute coronary syndrome, 25
with coronary artery disease, 13, 20
in diabetic nephropathy, 130
with heart failure, 6-8
Hyperparathyroidism
and growth retardation in children with CRI and in dialyzed children, 465
in hypertensive ESRD, 151
pathogenesis of secondary, in pediatric renal osteodystrophy, 441-443
Hypersensitivity reactions, *see* Anaphylactoid reactions
Hypertension (HTN)
in diabetic nephropathy, 126-129, 131
in DM with CV disease, 74
in edema patients on HD, 286-288, 292, 293
essential, genetic disorders of ENaC in, 88-89

malignant, patterns of, 335-336
in pediatric ADPKD, 430-432
preventing progression of pediatric ADPKD with, 430-432
see also Hypertension in CV disease with renal disease; Hypertension in ESRD; Hypertension in inner city renal disease patients; Hypertensive disorder(s) of pregnancy
Hypertension (HTN), and medication-related renal dysfunction in urban HIV-infected patients, 386-393
dysfunction due to antiretroviral drugs, *see* Antiretroviral drugs for urban HIV-infected patients, renal dysfunction due to
primary and secondary systemic, 386-387
pulmonary, 386
Hypertension (HTN) in CV disease with renal disease
with acute coronary syndrome, 25
with atheroembolic renal disease, 44
with CAD, 13
in heart failure, 3-6, 8, 9
with pericardial disease, 53
Hypertension (HTN) in ESRD, 146-156
background, epidemiology, and prevalence of, 146-149
outcome and therapy of, 150-153, 193-194
pathogenesis of, 147-149
and rHuEPO therapy, 150-151, 196
see also Hypertension in inner city renal disease patients
Hypertension (HTN) in inner city renal disease patients, 329-337, 341, 342
"benign" hypertensive nephrosclerosis, 334-335
cocaine use and, 363, 364
control of, at Vicenza dialysis center, 350, 351
HIVAN and, 394, 395
income disparities in outcome of, 380, 381
malignant, 335-336
see also Hypertension, and medication-related renal dysfunction in urban HIV-infected patients
Hypertensive disorder(s) of pregnancy, 182-187
in chronic renal parenchymal disorders, 179-181
classification of, 183-184
preeclampsia-eclampsia as, *see* Preeclampsia-eclampsia
see also Hypertensive pregnancy, kidney and
Hypertensive nephrosclerosis, "benign", 334-335
Hypertensive pregnancy, kidney and, 173-189
and hypertensive disorders, *see* Hypertensive disorder(s) of pregnancy
renal physiological adaptations to pregnancy and, *see* Renal physiological adaptations to pregnancy
in transplant recipients, 181-182
Hypertrophy
glomerular, GS and, 545-546
tubular, tubulointerstitial injury and, 559-560
see also Left ventricular hypertrophy in renal disease
Hypervolemia in pregnancy, 178-179
Hypokalemic distal renal tubular acidosis (dRTA), 100-103
assessment and therapy of, 102-103
Cl/HCO_3 exchanger in, 101-102
distal nephron tightness in, 102
H,K-ATPase in, 100-101
Hyponatremia, edema and, 269-272
dilutional, in cirrhosis, 315-316
nonosmotic vasopressin secretion in, 269
renal concentrating mechanism in, 269-270
V_2 receptor antagonists and, 269-273, 315
Hypotension
in cirrhosis with ascites, 314
in edema patients on HD, 286-287, 292, 295
in ESRD children on HD, factors involved in, 475
Hypothalamic disorders, luteinizing hormone in cyclic idiopathic edema associated with, 245

Ibitulide, 60, 61
ICD (implantable cardioverter-defibrillator), 58-59
IDDM (insulin-dependent diabetes mellitus), *see* Diabetic nephropathy *and entries beginning with terms*: Diabetes mellitus
Idiopathic edema, *see* Cyclic idiopathic edema
Idiopathic heart failure, 275
Idiopathic (minimal change) nephrotic syndrome, ARF and, 252-253
IGF-1, *see* Insulin-like growth factor-1
IL-2R (interleukin-2R) inhibitors, 510, 514, 517
Immune injury, GS and, 546-547
Immunization, prevention of postrenal transplantation infections in children with, 528
Immunobiology of renal transplantation, 214
Immunoglobulin, varicella zoster, 524-527
Immunophilins, 510
Immunosuppression
in renal transplantation, 214-215, 217-218
see also Immunosuppression in pediatric renal transplantation *and specific immunosuppressive agents*
Immunosuppression in pediatric renal transplantation, 502-504, 508-520
with calcineurin inhibitors, 510-511, 516, 517; *see also* Cyclosporine; FK506
with costimulatory molecules, 514-515
glucocorticoid targets in, 508-510
with IL-2R blockade, 510, 514, 517
with mTOR inhibitors, 511-512
optimal approach to, 515-517
with purine antagonists, 512-513; *see also* Azathioprine; Mycophenolate mofetil
with T-cell surface molecules, 513-514
Implantable cardioverter-defibrillator (ICD), 58-59
Incidence
of arrhythmias, 59-60
of CIRF, 39
of pediatric renal transplantation rejection, 501-502, 505
of urban HIVAN, 395-398
see also Prevalence *and specific conditions*
Income-based disparities, effects of, on urban renal disease patient outcome, 377-385
on health insurance status, 381-382
on mortality, 379-381
patient demographics according to income, 379, 380
in transplant waiting list placement, 377-378, 381, 382
Indapamide, 70
Indications
for vitamin D therapy in pediatric renal osteodystrophy, 447
see also specific conditions and therapeutic modalities
Indinavir, 342, 386, 387, 389
Indomethacin, 540

Induction immunosuppression in pediatric renal transplantation, 517
Infant mortality among urban African-Americans, 357
Infarction, *see* Myocardial infarction in renal disease
Infections, *see* Postrenal transplantation infections, pediatric
Inflammation, P_{if} in, 224-225
Inflammatory injury, GS and, 546-547
Influenza infections, postrenal transplantation, in children, 526
Information, patient, *see* Patient education and information
Inherited diabetes insipidus, *see* Diabetes insipidus, aquaporin-2 in
Initiation
  of diabetic and nondiabetic renal disease, genetic variability of RAS and, 585-586
  of dialysis at Vicenza dialysis center, 347
Injury, *see* Angiotensin II in GS; Angiotensin II in tubulointerstitial injury; Burn injury, edema and *and specific conditions*
Inner city renal disease patients, reflections on care of, 329-333
  hospital location and, 331
  lack of black nephrologists on hospital staff, 330-331
  need for patient and community education, 332-333
  racism and, 332-333
  role of university-industrial complex in, 331-332
  see also Urban renal disease
Inotropic agents, 16
Insulin-dependentd diabetes mellitus, *see* Diabetic nephropathy *and entries beginning with terms*: Diabetes mellitus
Insulin-like growth factor-1 (IGF-1)
  in diabetic nephropathy, 126
  in UTO, 135, 140
Insulin therapy, 129, 225
Insurance, *see* Health insurance status of urban renal disease patients
Integration of therapies at Vicenza dialysis center, 348-349
β_1-Integrins, *see* Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of
Interferon, 524-526
Interleukin-2R (IL-2R) inhibitors, 510, 514, 517
Intermediate outcome of HD, *see* Outcome, intermediate HD, in Singapore
Interstitial cerebral edema, 306
Interstitial fibrosis, *see* Tubulointerstitial fibrosis
Interstitial fluid hydrostatic pressure (P_{if}), role of β_1-integrins in control of, 222-230
  in burn injury, 223-224
  in inflammation, 224-225
  mechanism of action of β_1-integrins, 225
  normal transcapillary exchange and, 222-223
  PDGF-BB attenuating lowering of P_{if}, 227
  physiologic functions of, 226-227
  prostaglandins and, 227-228
  structure of β_1-integrins, 225-226
Intoxication, *see* Toxicity
Intrahepatic portosystemic shunt, *see* Transjugular intrahepatic portosystemic shunt
Intraluminal renin-angiotensin system (RAS), protection of, 598-600
Intrarenal renin-angiotensin systems (RAS), protection of, 593-602
  intraluminal RAS, 598-600
  RAS and renal hemodynamics in diabetic nephropathy, 597-598
  tissue RAS and proinflammatory and profibrotic responses to renal injury, 596-597
Intravascular ultrasound (IVUS) for CAD in renal disease, 18-19
Invasive testing for CAD in ESRD, 18-19
Irbesartan, 69, 558, 597
Iron therapy at Vicenza dialysis center, 351
Ischemic heart failure, 275
Isoniazid, 523, 527
Isorbide, 69
Isradipine, 69, 389
IVUS (intravascular ultrasound) for CAD in renal disease, 18-19

K (potassium), *see* H,K-ATPase; Hyperkalemia; Hypokalemic distal renal tubular acidosis; Na^+, K^+, $2Cl^-$ cotransporter
K (potassium)-sparing diuretics, *see* Diuretics
Kabi International Growth Study of rGH effects on dialyzed ESRD children adult height, 491
Kappa (κ) opioid agonists, 315
Ketoconazole, 431, 434
Kie (transcellular urea mass transfer coefficient), defined, 476
Kt/V, *see* Adequacy of dialysis

Labetalol, 69
Lamifiban, 30
Lamivudine, 386-388, 524
Late first acute rejection episode in pediatric renal transplantation, outcome of, 504
Laxatives, 244, 247, 248
Left ventricular dysfunction, and heart failure in renal disease, 3-7, 9
  hypertension and, 5-6
  risk factors for, 4-7
  uremia, metabolic alterations and, 7
  ventricular volume overload and, 6-7
Left ventricular hypertrophy (LVH) in renal disease
  in arrhythmias, 57, 63
  in CAD, 14
  in heart failure, 3-7, 9
  in HTN of ESRD, 148
  in pericardial disease, 53
Liddle's syndrome (pseudoaldosteronism), 86-87
Lidocaine, 58, 69, 389
Life cycle of erythropoiesis, 191-192
Life expectancy of urban African-Americans, 356-357
Lipid-lowering drugs (β-hydroxy-β-methylglutaryl-coenzyme A reductase inhibitors; statins), 20, 130, 351, 434-435
Lisinopril, 70, 74, 75
Lithium, 98, 99, 234-235, 323-326
Liver cirrhosis, *see* Cirrhosis, edema with
Liver transplantation
  for cirrhosis with ascites, 313-314
  for hepatorenal syndrome, 56
Local factors
  in ascites of cirrhosis, 308-309
  in edema of ARF, 241
Loop diuretics, *see* Diuretics
Lopinavir, 389

Lopressor, 19
Losartan
in CV disease with renal disease, 9, 69, 75
in HIV infection, 389
for HTN of pediatric ADPKD, 431, 432
progression of renal disease and, 540, 565, 567, 570, 573
Lovastatin, 130, 431, 434
Lupus nephritis in inner city residents, 339-340, 406-408
Luteinizing hormone, role of, in cyclic idiopathic edema associated with hypothalamic disorders, 245
LVH, *see* Left ventricular hypertrophy in renal disease
Lymphoscintigraphy, two-compartment, in cyclic idiopathic edema, 248-249

McKendry criteria for cyclic idiopathic edema diagnosis, 244, 245, 248
Macrophage/monocyte infiltration in tubulointerstitial injury, ANG II and, 558
Magnesium sulfate, 187
Maintenance immunosuppression in pediatric renal transplantation, 517
Malignant hypertension (HTN), urban renal disease patients with, 335-336
Malnutrition, growth retardation due to, in dialyzed ESRD children, 464-465
Mannitol, 41, 42, 164, 306, 476
Mechanism of action of β_1-integrins in control of P_{if}, 225
Meclofenomate, 167
Medical insurance, *see* Health insurance status of urban renal disease patients
Medical management, *see* Drug therapy of CV disease in renal disease; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients *entries beginning with terms*: Cardiovascular drugs *specific conditions and specific drugs*
Medicare end-stage renal disease (ESRD) program, rHuEPO therapy and
cost of rHuEPO and, 197-198
hematocrit target setting in children and, 457
see also Medicare end-stage renal disease program for urban renal disease patients
Medicare end-stage renal disease (ESRD) program for urban renal disease patients, 400, 412, 415
attributes of, 359, 360
patient access to cardiac procedures and, 367, 370-372, 374, 375
patient outcome, 356, 360, 377, 379, 381-384
yearly expenditures of, 330
Metabolic acidosis
and growth retardation in dialyzed ESRD children, 465
normal anion gap hyperchloremic, conditions associated with, 95
see also Distal renal tubular acidosis
Metabolism
alterations in, in CAD, 7
altered PTH, and secondary hyperparathyroidism in pediatric renal osteodystrophy, 442-443
drug, in renal disease, 67
renal, UTO effects on, 134
see also Metabolic acidosis
Metformin, 41, 43-44, 129
Methyldopa, 70, 247, 336
Methylprednisolone, 406, 431, 501-503
Metoclopramide, 246
Metolazone, 69, 266
Metoprolol
in CV disease with renal disease, 19, 25, 28, 60, 68-70, 162
in HIV, 387, 389
interactions with, 387, 389
Metropolitan areas with highest number of HIVAN cases, 396
Mexiletene, 58, 69, 389
MI, *see* Myocardial infarction in renal disease
Middle-molecular-weight uremic toxins, and pediatric HD adequacy, 475-477
Mild ascites, practical approach to patients with, 314
Milrinone, 70
Mineralocorticoids, *see* Steroids
Minimal change (idiopathic) nephrotic syndrome, ARF and, 252-253
Minorities, *see* Urban renal disease
Minority Organ Tissue Transplant Education program, *see* Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of
Minoxidil, 19, 69, 247, 336
MMF, *see* Mycophenolate mofetil
Moderate ascites, practical approach to patients with, 314
MODS (multiple organ dysfunction syndrome), ARF with edema and, 253
Molecular aspects of fluid regulation by urodilatin, 239-240
Molecular pathology
of heart failure, 275
of pediatric renal transplantation rejection, 500, 502
Molecular structure
of endogenous EPO, 190-191
of β_1-integrins, 225-226
Monitoring pediatric HD session, 476-477
Monoamine oxidase inhibitors, 247
Monoclonal antibodies, *see specific monoclonal antibodies*
Monocyte/macrophage infiltration in tubulointerstitial injury, ANG II and, 558
Morbidity
of CIRF, 38-39
rHuEPO-associated, in dialyzed ESRD children and in CRI children, 454-455
see also Associated conditions *and specific conditions*
Moricizine, 58, 68
Mortality
adult and infant, in inner city neighborhoods, 357
see also Mortality of renal disease patients *specific conditions*
Mortality of dialyzed ESRD children
on CPD, 484
and CRI children, rHuEPO effects on, 454-455
Mortality of inner city renal disease patients
and income-based disparities, 379-381
in Singapore, 416
Mortality of renal disease patients
with CIRF, 38-43
rHuEPO therapy effects on, 195
see also Mortality of dialyzed ESRD children; Mortality of inner city renal disease patients
Mottep (Minority Organ Tissue Transplant Education program)

model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of, 419-428
demographics of respondents to study, 423-424
postseminar/presentation results, 424-426
recommendations on, 427
study limitations, 423
mTOR inhibitors, immunosuppression with, 511-512
Multicenter study of outcomes with normalized hematocrit, 457-458
Multiple organ dysfunction syndrome (MODS), ARF with edema and, 253
Muscle relaxants, 253
Mutations of *PKD1* and *PKD2* genes in ADPKD, 108-110
somatic second hit, 109-110
Mycophenolate mofetil (MMF)
in nephrotic edema, 266
in pediatric renal transplantation, 512, 513, 516, 517, 523
in renal transplantation, 182, 214-216
Mycophenolic acid, 512, 513
Myocardial infarction (MI) in renal disease
acute coronary syndrome and, 25, 30, 32
arrhythmias and, 57, 58
coronary interventions and, 36, 37
and coronary revascularization in renal transplant candidates, 47, 49
heart failure and, 4-6
pericardial disease and, 52
see also Acute myocardial infarction with ST segment elevation in renal disease, management of; Non-Q wave myocardial infarction in renal disease, management of
D-Myo-inositol-1,2,6-triphosphate (α-trinositol), 225, 227
Mystixin, 225

Na (sodium)
delivery of distal, in hyperkalemic dRTA, 98-99
in preascitic stage of cirrhosis, 317-322
removal of, dry body weight and, 292-295
tubular reabsorption of, by lithium clearance in cirrhosis, 323-326
see also Atrial natriuretic peptide(s); Congestive heart failure with cirrhosis, Na and water retention in; Dry body weight, Na balance and; Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and; Hyponatremia, edema and; Na kinetic model; Na^+,Cl^- cotransporter; Na^+,H^+ exchanger isoform 3; Na HCO_3; Na^+,K^+,2Cl^- cotransporter; Renal apical Na^+ transporters, genetic disorders of
Na (sodium) kinetic model, 294-295
Na^+,Cl^- (sodium,chloride; NCC) cotransporter, thiazide-sensitive, genetic disorders of, 84-85
Na^+,H^+ (sodium,hydrogen) exchanger isoform 3 (NHE3), genetic disorders of, 83
Na HCO_3 (sodium bicarbonate), 431, 435
Na,K-ATPase, *see* Hyperkalemic distal renal tubular acidosis, defective basolateral Na,K-ATPase and
Na^+,K^+,2Cl^- (sodium,potassium,chloride) cotransporter, genetic disorders of, 83-84
Nadolol, 70
Nafcillin, 523
L-NAME (L-nitro-arginine-methyl ester) in UTO, 141
National Kidney Foundation-Dialysis Outcomes Quality Initiative (NFK-DOQI), and Medicare hematocrit targets in children, 457
National Kidney Foundation-Singapore, *see* Dialysis for urban ESRD patients in Singapore, funding of, through charity
Natriuretic factors, *see* Atrial natriuretic factors, adsorption of, in uremia
Natriuretic peptides, atrial, *see* Atrial natriuretic peptide(s)
NCC (Na^+,Cl^- cotransporter), thiazide-sensitive, genetic disorders of, 84-85
NDI (neurogenic diabetes insipidus), acquired, aquaporin-2 in, 234-236
Neighborhood income, *see* Income-based disparities, effects of, on urban renal disease patient outcome
Nelfinavir, 389, 390
Neoral, *see* Cyclosporine
Nephritic edema, 257-261
Nephron, distal, *see* Distal nephron
Nephrosclerosis, "benign" hypertensive, 334-335
Nephrotic edema, 262-268
ARF and, 252-253
colloid osmotic pressure in, 267
pathogenesis of, 263-266
pulse Reverse Osmosis Hypothesis of, 266-267
therapy of, 266
Nephrotic syndrome, idiopathic, ARF and, 252-253
Nervous system, sympathetic, activation of, in HTN of ESRD, 150
Neurodevelopment of children on CPD, as index of nutritional status, 487
Neurogenic diabetes insipidus (NDI), acquired, aquaporin-2 in, 234-236
Neurogenic inflammation, P_{if} in, 224-225
Nevirapine, 388
New York City, number of AIDS and HIVAN cases in, 395-398
NFAT (nuclear factor of activated T cells), as calcineurin target, 510-511
NF-κB, *see* Nuclear factor-κB
NFK, *see* Dialysis for urban ESRD patients in Singapore, funding of, through charity; National Kidney Foundation-Dialysis Outcomes Quality Initiative
NHE3 (Na^+,H^+ exchanger isoform 3), genetic disorders of, 83
Nicardipine, 69, 75, 387, 389
Nicotinic acid, 20
NIDDM (non-insulin-dependent diabetes mellitus), *see* Diabetic nephropathy *and entries beginning with terms*: Diabetes mellitus
Nifedipine
aquaporins and, 235
for CV disease with renal disease, 61, 69, 75
in diabetic nephropathy, 129
for urban renal disease patients, 336, 387-389
Nimodipine, 389
Nisoldipine, 69, 389
Nitrates, 9, 28, 163
Nitrendipine, 387, 389
L-Nitro-arginine-methyl ester (L-NAME) in UTO, 141
Nitroglycerin, 25, 28, 33, 69, 163
Nondiabetic renal disease, *see* Genetic variability of RAS in diabetic and nondiabetic renal disease
Nonhemodynamic mechanisms
of aldosterone, progression of renal disease and, 576-577

of ANG II in GS, 545
Non-insulin-dependent diabetes mellitus, *see* Diabetic nephropathy *and entries beginning with terms*: Diabetes mellitus
Noninvasive diagnosis of CAD in renal disease, 14-18
with electron-beam computed tomography, ankle-arm BP index, and serum markers, 18
with nuclear scintigraphy, 15-17
with stress echocardiography, 14-17
Noninvasive diagnosis of CV disease in renal disease
of acute coronary syndrome, 26
see also Noninvasive diagnosis of CAD in renal disease
Nonnucleoside analogue reverse transcriptase inhibitors, 388
Nonosmotic vasopressin (antidiuretic hormone; arginine-vasopressin), secretion of, in edema patients on HD, 269
Nonpharmacologic therapy
of CAD in renal disease, 20-21
see also specific nonpharmacologic therapeutic modalites; for example: Dietary therapy
Non-Q wave myocardial infarction (MI) in renal disease, management of, 25, 29-33
medical management of, 29-30
revascularization procedures for, 30-33
Nonsteroidal anti-inflammatory drugs (NSAIDs)
for CHF with cirrhosis, 165, 167
for CV disease with renal disease, 40, 41, 55
in edema, 247, 248, 253
for urban renal disease patients, 362
Nonsustained ventricular tachycardia (NSVT) in renal disease, 57-58
Normal anion gap hyperchloremic metabolic acidosis, conditions associated with, 95
Normal biology of TGF-β, 563-564
Normal transcapillary exchange, P_{if} and, 222-223
Normalization of hematocrit with rHuEPO in dialyzed children and in CRI children, 455, 457-458
North American Pediatric Transplant Cooperative Study Registry on rGH effects on dialyzed ESRD children adult height, 492
NSAIDs, *see* Nonsteroidal anti-inflammatory drugs
NSVT (nonsustained ventricular tachycardia) in renal disease, 57-58
Nuclear factor of activated T cells (NFAT), as calcineurin target, 510-511
Nuclear factor-κB (NF-κB)
in tubulointerstitial injury, ANG II and, 559
in UTO, 135, 137, 139-140, 142
Nuclear scintigraphy of CAD in renal disease, 15-17
Nucleoside analogue reverse transcriptase inhibitors, 388
Nucleotide analogues, 388
Nutritional status of dialyzed ESRD children
of children on CPD, outcome and, 485-487
and growth retardation due to malnutrition, 464-465
see also Dietary therapy

Obstructive uropathy, *see* Urinary tract obstruction
ODN (oligodeoxynucleotides), TGF-β antisense, 143
OKT3, 503, 513-515, 517, 523
Oligodeoxynucleotides (ODN), TGF-β antisense, 143
OP-1 (osteogenic protein-1) for UTO, 142
Opening of BBB in vasogenic cerebral edema, 303-304
Organ donations, *see* Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of
Ornipressin, 167
Oseltamivir, 526
Osmoregulation in pregnancy, 176-178
Osmosis, pulse reverse, in nephrotic edema, 266-267
Osmotic gradients, cerebral edema due to, 306
Osmotic pressure, colloid, in nephrotic edema, 267
Osteodystrophy, *see* Pediatric renal osteodystrophy with CRI and ESRD
Osteogenic protein-1 (OP-1; bone morphogenetic protein-7) for UTO, 142
Osteopontin in tubulointerstitial injury, ANG II and, 557
Outcome
ESRD, *see* Outcome of dialyzed ESRD children; Outcome of urban ESRD patients
of first acute rejection episode in pediatric renal transplantation, 504
of HTN in ESRD, 151-153
see also Acute and chronic rejection of pediatric renal transplantation; Adverse effects; Mortality *and specific conditions*
Outcome, intermediate HD, in Singapore, 414-416
and HD practices, 415-416
and in U.S., compared, 414-415
Outcome of dialyzed ESRD children
growth retardation and, 467-468
see also Clinical effects of rHuEPO therapy in dialyzed ESRD children and in CRI children; Outcome of pediatric CPD for ESRD
Outcome of pediatric CPD for ESRD, 483-487
hospitalization rate, 484-485
measures of, 484
mortality, 484
nutritional status and, 485-487
quality of life, 487
and technique survival, 485
Outcome of urban ESRD patients, 359-360
see also Mortality of inner city renal disease patients; Outcome of urban ESRD patients in Singapore; Patient survival, inner city; Socioeconomic status of urban renal disease patients
Outcome of urban ESRD patients in Singapore
intermediate, *see* Outcome, intermediate HD, in Singapore,
mortality, 416
rehabilitation, 416-417
Overflow theory of nephrotic edema, 263-265
Oxidative stress in UTO, 137-138

P carinii (*Pneumocystis carinii*) pneumonia infection, postrenal transplantation, in children, 527
PAC(s) (premature atrial contractions) in renal disease, 63-64
Pacemakers
for arrhythmias, 62
for CHF, 62-63
PAI-1 (plasminogen activator inhibitor-1), ANG II and, in GS, 548
Palivizumab, 526
PAN (puromycin aminonucleoside), 235, 236
Pancreas transplantation, renal and, for diabetic nephropathy, 131

Paracentesis
for cirrhosis with ascites, 312-315
for dialysis pericarditis, 55
Parathyroid hormone (PTH)
in HTN of ESRD, 151
in secondary hyperparathyroidism of pediatric renal osteodystrophy, 442-443
Parenchymal disorders, chronic renal, hypertensive pregnancy with, 179-181
Parvovirus infections, postrenal transplantation, in children, 526
"Passive" control of interstitial fluid volume, 223
Pathology (and pathogenesis)
of acute coronary syndrome, 26
of AQP2, 232
of atheroembolic renal disease, 44
of CIRF, 40-41
cyst, in ADPKD, 113
of dialysis pericarditis, 54
of edema in heart failure, 278
of fluid distribution in body compartments in cyclic idiopathic edema, 244-245
of HTN in ESRD, 147-149
molecular, of pediatric transplantation rejection, 500-502
of nephrotic edema, 263-266
of secondary hyperparathyroidism in pediatric renal osteodystrophy, 441-443
of urodilatin, 241-242
see also Pathology of CHF; Pathology of cirrhosis; Pathology of heart failure *and specific conditions*
Pathology (and pathogenesis) of CHF, 159-163
renal Na handling in, 159-161
renal water handling in, 161-162
therapy based on, 162-163
Pathology (and pathogenesis) of cirrhosis, 163-168
with ascites with cirrhosis, 312-315
of Na handling, 164-165
therapy based on, 167-168
of water handling, 165-167
Pathology (and pathogenesis) of heart failure, 273-278
apoptosis in, 274-275
arrhythmogenesis of, 275-276
cytokines in, 274
endothelial dysfunction in, 276
endothelin in, 273-274, 277
of ischemic versus idiopathic heart failure, 275
molecular changes in, 275
remodeling in, 276-277
Pathophysiology of RAS, 582-584, 588
Patient characteristics, *see* Demographics
Patient education and information
choice of therapies at Vicenza dialysis center based on, 348
on renal disease in inner city neighborhoods, need for, 332-333
see also Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of
Patient survival, inner city
with HIVAN, 400-401
in urban dialysis centers, 359-360
see also specific conditions
Patient's responsibilities in cyclic idiopathic edema diagnosis, 248
Patterns of inner city renal disease, 334-345
of "benign" hypertensive nephrosclerosis, 334-335
cocaine and, 336
of FSGS, 336-338
of heroin-associated nephropathy and HIVAN, 338-339
of lupus nephritis, 339-340
of malignant hypertension, 335-336
of renal failure, 341-342
of sickle glomerulopathy, 340-341
PDGF, *see* Platelet-derived growth factor
PDGF-BB (platelet-derived growth factor-BB) in attenuating P_{if}, 227
Pediatric autosomal dominant polycystic kidney disease (ADPKD), preventing progression of, 430-440
of ADPKD with HTN and proteinuria, 430-432
with dietary therapy, 431-435
with therapies targeting cystic phenotype of PKD epithelium, 435-437
Pediatric chronic renal insufficiency and ESRD
introduction to, 429
see also Acute and chronic rejection of pediatric renal transplantation; Adequacy of pediatric CPD for ESRD; Growth retardation of dialyzed ESRD children; Hemodialysis for pediatric ESRD; Immunosuppression in pediatric renal transplantation; Pediatric autosomal dominant polycystic kidney disease, preventing progression of; Pediatric renal osteodystrophy with CRI and ESRD; Postrenal transplantation infections, pediatric; rGH therapy of dialyzed ESRD children; rHuEPO therapy for anemia in dialyzed ESRD children and in CRI children
Pediatric renal osteodystrophy with CRI and ESRD, 441-450
as factor in growth retardation, 465
pathogenesis of secondary hyperparathyroidism and, 441-443
prevention and treatment of, *see* Prevention and treatment of pediatric renal osteodystrophy with CRI and ESRD
Pediatric renal transplantation, *see* Acute and chronic rejection of pediatric renal transplantation; Immunosuppression in pediatric renal transplantation; Postrenal transplantation infections, pediatric
Pentamidine, 524
Pentoxifylline, 16
Peptides, *see* Atrial natriuretic peptide(s)
Perceived need for organ donation by Mottep study respondents, 424
Perceptions of participants in Mottep study, changes in, 424-427
education-based changes, 426, 427
race-based changes, 425-426
Percutaneous coronary angiography and/or angioplasty, renal implications of, 36-46
for atheroembolic renal disease, 44-45
for CAD, 18-19, 21
guidelines for performing, in patients on metformin therapy, 43-44
radiographic contrast agents in, *see* Contrast agents for percutaneous coronary interventions in renal disease
see also Percutaneous transluminal coronary angioplasty in renal disease patients

Percutaneous revascularization, *see* Coronary revascularization in renal transplant candidates, risk and benefit of
Percutaneous transluminal coronary angioplasty (PTCA) in renal disease patients
  for acute coronary syndrome, 30-32
  for CAD, 21
  radiographic contrast agents used for, *see* Contrast agents for percutaneous coronary interventions in renal disease
Pericardial disease in renal disease, 52-56
  hepatorenal syndrome and, 56
  pericarditis as, *see* Uremic pericarditis in renal disease
Pericarditis in renal disease
  dialysis, 54-55
  uremic, *see* Uremic pericarditis in renal disease
Peripheral edema, 247
Peritoneal access methods used at Vicenza dialysis center, 348
Peritoneal dialysis
  dose and adequacy of, and Kt/V, 206
  see also Adequacy of pediatric CPD for ESRD; Dialysis
Peritoneal transport, characteristics of, CPD adequacy and, 482
Peritoneovenous shunt for ascites in cirrhosis, 313
PFD (pirferidone), 142-143
PG(s) (prostaglandin) in P_{if} control, 227-228
PGE_2 (prostaglandin E_2), P_{if} and, 227-228
$PGF_{2\alpha}$ (prostaglandin $F_{2\alpha}$) in P_{if} control, 227-228
PGI_2 (prostaglandin I_2) in P_{if} control, 227-228
PHA (pseudohypoaldosteronism), hyperkalemic dRTA and, 97-98
PHA-1 (pseudohypoaldosteronism type 1), 87-88, 97, 98
PHA-2 (pseudohypoaldosteronism type 2), 97, 98
Pharmacology
  of rHuEPO, 192
  see also Cardiovascular drugs, pharmacology of, in renal disease *and specific drugs*
Phenotype, cystic PKD epithelium, therapies targeting, in prevention of ADPKD, 435-437
Phenylpropanolamine, 386-387
Phenytoin, 187
Phosphorus
  and growth retardation in dialyzed ESRD children, 464
  in pediatric renal osteodystrophy, 441, 443-444
Physician's responsibilities in cyclic idiopathic edema diagnosis, 248
Physiologic functions of β_1-integrins, 226-227
Physiology
  of endogenous EPO and, 190-192
  of renal aquaporins, *see* Aquaporin(s)
  of urodilatin, 240-241
  see also Physiologic functions; Renal physiological adaptations to pregnancy
P_{if}, *see* Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of
Pindolol, 69
Pindoprolol, 389
Pirferidone (PFD), 142-143
Pitressin, 177
PKD (polycystic kidney disease), *see* Autosomal dominant polycystic kidney disease
PKD1 and *PKD2* genes in ADPKD, *see* Mutations of *PKD1* and *PKD2* genes in ADPKD; Polycystin-1 in ADPKD; Polycystin-2 in ADPKD
Placement of urban renal disease patients on transplant waiting list, income and, 377-378, 381
Plasma refilling rate (PRR) in HD patients, 287-289
Plasma volume, continuous measurement of, in HD patients, 288-289
Plasminogen activator inhibitor-1 (PAI-1), ANG II and, in GS, 548
Platelet-derived growth factor (PDGF)
  in diabetic nephropathy, 126
  in renal disease progression, 576
  in UTO, 135
Platelet-derived growth factor-BB (PDGF-BB) attenuating P_{if} lowering, 227
Platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors for acute coronary syndrome in renal disease, 25, 28, 30, 32
Pneumocystis carinii (*P carinii*) pneumonia infection, postrenal transplantation, in children, 527
Polycystic kidney disease, *see* Autosomal dominant polycystic kidney disease
Polycystin-1 in ADPKD, 110-113
  cyst growth, ECM remodeling and, 117-118
  described, 110-112
  localization of, 112-113
  signal transduction and, 112
Polycystin-2 in ADPKD, 110-113
  described, 110-112
  localization of, 112-113
  signal transduction and, 112
Polygeline, 313
Polymixin B, 225
Polymorphism
  ACE gene, 73, 580, 583, 586-588
  significance of RAS-related gene polymorphisms in GS progression, 547-548
  see also Mutations of *PKD1* and *PKD2* genes in ADPKD
Polyoma infections, postrenal transplantation, in children, 527
Polyuric conditions, aquaporin-2 in, 234-236
Population served by Vicenza dialysis center, 346-347
Portosystemic shunt, transjugular intrahepatic, *see* Transjugular intrahepatic portosystemic shunt
Postdialytic dry weight adjustment in pediatric HD, 474-475
Postrenal transplantation infections, pediatric, 521-531
  antimicrobial agents for bacterial infections, 523; *see also* Antimicrobial agents for pediatric postrenal transplantation infections
  future directions, 528-529
  prevention of, 527-528
  risk of, 521
  special considerations on, 521-522
Postseminar/presentation results of Mottep study, 424-426
Potassium, *see* H,K-ATPase; Hyperkalemia; Hypokalemic distal renal tubular acidosis; Na^+, K^+, $2Cl^-$ cotransporter
Potassium citrate, 431, 435
Potassium-sparing diuretics, *see* Diuretics
Poverty, *see* Urban renal disease
Practical basis of blood purification, 471-472
Prazosin, 69, 389
Preascitic stage of cirrhosis, Na retention in, 317-322
Prednisolone, 339
Prednisone, 182, 337-339, 431, 434, 512, 514-516
Preeclampsia-eclampsia, 183-187

diagnosis of, 183-184
etiology of, 184-185
prediction and prevention of, 185-187
therapy and management of, 187
Pre-end-stage renal disease (ESRD) care at Vicenza dialysis center, 347
Pregnancy, *see* Hypertensive pregnancy, kidney and
Premature atrial contractions (PACs) in renal disease, 63-64
Premature ventricular contractions (PVCs) in renal disease, 57-58
Prescription of pediatric HD, 476-477
Presentation/postseminar results of Mottep study, 424-426
Pressure, *see* Blood pressure; Colloid osmotic pressure; Interstitial fluid hydrostatic pressure, role of β_1-integrins in control of; Pressure system
Pressure system in HD, time, defined, 473
Prevalence
of growth retardation in ESRD children, 464
of HTN in ESRD, 146-148
of urban HIVAN, 395-298
see also Incidence *and specific conditions*
Prevention
of CIRF, 41-43
of postrenal transplantation infections in children, 527-528
of preeclampsia, 185-187
see also Pediatric autosomal dominant polycystic kidney disease, preventing progression of; Prevention and treatment of pediatric renal osteodystrophy with CRI and ESRD
Prevention and treatment of pediatric renal osteodystrophy with CRI and ESRD, 443-448
with calcimimetics, 448
with serum phosphorus control, 443-444
with vitamin D, *see* Vitamin D for pediatric renal osteodystrophy
Primary systemic hypertension (HTN) in urban HIV-infected patients, renal dysfunction and, 386-387
Private insurance, *see* Health insurance status of urban renal disease patients
ProANPs, *see* Atrial natriuretic factors, adsorption of, in uremia
Probenecid, 388
Probucol, 431, 434
Procainamide, 58, 68-70
Profibrotic responses, proinflammatory and, to renal injury, tissue RAS and, 596-597
Progesterone in cyclic idiopathic edema, 247
Progression of renal disease
of ADPKD, *see* Pediatric autosomal dominant polycystic kidney disease, preventing progression of
CCB effects on, 75
introduction to, 533-534
see also Renin-angiotensin system in progression of renal disease
Progressive loss of renal function in diabetic and nondiabetic renal disease, genetic variability of RAS and, 586
Proinflammatory responses, profibrotic and, to renal injury, tissue RAS and, 596-597
Prolonged hemodialysis (HD) for HTN control in ESRD, 152-153
Propafenone, 58, 61, 69, 387, 389
Prophylaxis, *see* Prevention
Propranolol, 61, 68, 70, 387
Prostacyclin (PGI_2) in P_{if} control, 227-228
Prostaglandin(s) (PG) in P_{if} control, 227-228
Prostaglandin E_2 (PGE_2) in P_{if} control, 227-228
Prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$) in P_{if} control, 227-228
Prostaglandin I_2 (PGI_2) prostacyclin) in P_{if} control, 227-228
Protamine sulfate, 303-304
Protease inhibitors, 389-390
Protective effects of ACE inhibitors
cardiac and renal, 593-597
in GS, 544-553
Protein
intake of, and growth retardation in dialyzed ESRD children, 464-465
soy, in prevention of pediatric ADPKD, 431, 433
Protein restriction
in diabetic nephropathy, 130-131
in prevention of pediatric ADPKD progression, 431, 433
Protein trafficking in tubulointerstitial injury, ANG II and, 559
Protein-1, osteogenic, for UTO, 142
Proteinuria, pediatric ADPKD with, 430-432
PRR (plasma refilling rate) in HD patients, 287-289
Pseudoaldosteronism (Liddle's syndrome), 86-87
Pseudohypoaldosteronism (PHA), 97-98
Pseudohypoaldosteronism type 1 (PHA-1), 87-88, 97, 98
Pseudohypoaldosteronism type 2 (PHA-2), 97, 98
PTCA, *see* Percutaneous transluminal coronary angioplasty in renal disease patients
PTH, *see* Parathyroid hormone
Public funds for dialysis, *see entries beginning with term*: Medicare
Pulmonary fibrosis, hemodynamic-independent effects of ANG II receptor antagonists in, 571
Pulmonary hypertension (HTN) in urban HIV-infected patients, renal dysfunction due to, 386
Pulse Reverse Osmosis Hypothesis of nephrotic edema, 266-267
Purification, blood, *see* Blood purification
Purine antagonists, immunosuppression with, 512-513; *see also* Azathioprine; Mycophenolate mofetil
Puromycin aminonucleoside (PAN), 235, 236
PVCs (premature ventricular contractions) in renal disease, 63-64
Pyridoxine (vitamin B_6), 20
Pyrimethamine, 524

QOL, *see* Quality of life
Quality
dialysate, defined, 471
see also Quality of care, inner city; Quality of life
Quality of care, inner city
in dialysis centers, effects of, on patient outcome, 356-361
reflections on, *see* Inner city renal disease patients, reflections on care of
see also Urban renal disease
Quality of life (QOL)
as index of outcome for ESRD children on CPD, 487
see also Quality of life, rHuEPO effects on
Quality of life (QOL), rHuEPO effects on, 194
of children, 454
Quinapril, 70

Quinidine, 58, 61, 68, 70, 388, 390

Race
  altered perceptions of Mottep study participants based on, 425-426
  see also Urban renal disease *and specific conditions*
Racism, *see* Urban renal disease
Radiofrequency (RF) catheter ablation for arrhythmias, 61, 62
Radiographic contrast agents, *see* Contrast agents for percutaneous coronary interventions in renal disease
Ramipril, 70, 129, 162, 432, 594-596
RANTES (regulated on activation normal T-cell expression and secreted) in tubulointerstitial injury, ANG II and, 554, 559
Rapamycin, 510, 511-512, 514, 516, 517
RAS, *see* Renin-angiotensin system
Recombinant growth hormone, *see* rGH therapy of dialyzed ESRD children
Recombinant human erythropoietin, *see entries beginning with acronym*: rHuEPO
Recommendations, *see* Guidelines and recommendations
Refractoriness, *see* Resistance
Refractory ascites, practical approach to, 314
Regions with highest number of AIDS cases, 396
Regression, GS, with ACE inhibitors, 549-551
Rehabilitation of inner city ESRD patients
  in Singapore, outcome of, 416-417
  at Vicenza dialysis center, 351
Rejection, allograft, *see* Acute and chronic rejection of pediatric renal transplantation
Remodeling
  ECM, in ADPKD, 116-117
  heart, in heart failure, 276-277
Removal of Na, dry body weight and, 292-295
Renal apical Na^+ (sodium ion) transporters, genetic disorders of, 81-93
  of epithelial Na channel, *see* Epithelial Na channel, genetic disorders of
  of Na^+,H^+ exchanger isoform 3, 83
  of $Na^+,K^+,2Cl^-$ cotransporter, 83-84
  pseudoaldosteronism and, 86-87
  pseudohypoaldosteronism type 1 and, 87-88, 97, 98
  of thiazide-sensitive Na^+,Cl^- cotransporter, 84-85
Renal aquaporins, *see* Aquaporin(s)
Renal concentration mechanisms in hyponatremia with edema, 269-270
Renal development, ANG II role in, 539
Renal disease, *see* Progression of renal disease *and specific conditions*
Renal dysfunction
  and ascites in cirrhosis, 309-311
  effects of, on drug metabolism, 67
  see also Hypertension- and medication-related renal dysfunction in urban HIV-infected patients *and specific conditions*
Renal effects
  of ANG II fragments, renal disease progression and, 539-540
  of antiretroviral drugs, 390-391
  of percutaneous coronary intervention, *see* Percutaneous coronary angiography and/or angioplasty, renal implications of
  see also specific drugs and conditions
Renal failure
  chronic, *see* Dialysis; Hypertension in ESRD; Pediatric chronic renal insufficiency and ESRD; Renal transplantation *and entries beginning with acronym*: rHuEPO
  hyperaldosteronism in, 573-576
  in inner city renal disease patients, 341-342
  see also Acute renal failure; Contrast induced renal failure
Renal fibrosis
  hemodynamic-independent effects of ANG II receptor antagonists in, 565
  see also Tubulointerstitial fibrosis
Renal function
  ACE inhibitor effects on, 73-74
  effects of angiotensin II receptor antagonists on, 74
  in pediatric renal osteodystrophy, vitamin D effects on, 446
  progressive loss of, in diabetic and nondiabetic renal disease, genetic variability of RAS and, 586
  see also Renal dysfunction *and specific conditions*
Renal hemodynamics, *see* Diabetic nephropathy, renal hemodynamics in
Renal injury
  tissue RAS and proinflammatory and profibrotic responses to, 596-597
  see also Angiotensin II in tubulointerstitial injury *and specific injuries; for example*: Glomerulosclerosis
Renal insufficiency, *see* Pediatric chronic renal insufficiency and ESRD
Renal metabolism, UTO effects on, 134
Renal natriuretic peptide, *see* Atrial natriuretic peptide(s)
Renal osteodystrophy, *see* Pediatric renal osteodystrophy with CRI and ESRD
Renal parenchymal disorders, chronic, hypertensive pregnancy with, 179-181
Renal physiological adaptations to pregnancy, 173-179
  of GFR and RPF, 173-176
  of osmoregulation and fluid volume control, 176-178
  of total body water, 178-179
Renal plasma flow (RPF), adaptations of, to pregnancy, 173-176
Renal replacement therapies, *see* Dialysis; Renal transplantation
Renal transplantation, 213-219
  future of, 217-218
  history of, 47-48, 213-214
  and hypertension in subsequent pregnancy, 181-182
  immunobiology of, 214
  immunosuppression in, 214-215, 217-218; *see also specific immunosuppressive agents*
  pancreas and, for diabetic nephropathy, 131
  pediatric, *see* Acute and chronic rejection of pediatric renal transplantation; Immunosuppression in pediatric renal transplantation; Postrenal transplantation infections, pediatric
  placement of urban renal disease patients on waiting list for, income and, 377-378, 381, 382
  tolerance of, 216-217
  see also Coronary revascularization in renal transplant candidates, risk and benefit of; Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of
Renal tubules, *see* Distal renal tubular acidosis; Renal apical

Na^+ transporters, genetic disorders of *and entries beginning with element*: Tubul-
Renin-angiotensin II-aldosterone axis in cyclic idiopathic edema, 246-247
Renin-angiotensin-system (RAS) in renal disease progression in ESRD with HTN, 150
see also Aldosterone, progression of renal disease and; Angiotensin II, progression of renal disease and; Angiotensin II in GS; Angiotensin II in tubulointerstitial injury; Genetic variability of RAS in diabetic and nondiabetic renal disease; Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases; Intrarenal renin-angiotensin systems, protection of
Research pursued at Vicenza dialysis center, 353
Resistance
to aldosterone, *see* Pseudohypoaldosteronism; Pseudohypoaldosteronism type 1; Pseudohypoaldosteronism type 2
to diuretics, 71
to rHuEPO, 193-194
skeletal, to PTH actions in secondary hyperparathyroidism in pediatric renal osteodystrophy, 443
Respiratory syncytial virus infections, postrenal transplantation, in children, 526
Retrofiltration, defined, 472
Revascularization, *see* Coronary revascularization in renal transplant candidates, risk and benefit of
Reversal of pediatric renal transplantation rejection, 504
Reverse Osmosis Hypothesis, pulse, in nephrotic edema, 266-267
Reverse transcriptase inhibitors, 388
RF (radiofrequency) catheter ablation for arrhythmias, 61, 62
rGH (recombinant growth hormone) therapy of dialyzed ESRD children
growth-retarded children, 465, 467
on HD, 471
see also rGH therapy of dialyzed ESRD children, effects of, on adult height
rGH (recombinant growth hormone) therapy of dialyzed ESRD children, effects of, on adult height, 490-497
Belgian studies on, 491
conclusions on, 493-496
Dutch studies on, 490-491
German study on, 492-493
Kabi International Growth Study on, 491
North American Pediatric Transplant Cooperative Study Registry, 492
UK study on, 491-492
rHuEPO (recombinant human erythropoietin) therapy for anemia in dialyzed ESRD children and in CRI children, 451-462, 471
clinical effects of, *see* Clinical effects of rHuEPO therapy in dialyzed ESRD children and in CRI children
hematocrit and, *see* rHuEPO therapy for anemia in dialyzed ESRD children and in CRI children, hematocrit and
morbidity and mortality with, 454-455
rHuEPO (recombinant human erythropoietin) therapy for anemia in dialyzed ESRD children and in CRI children, hematocrit and
effects of, on growth, 455
hematocrit normalization, 455
hematocrit target level in, 457
rHuEPO (recombinant human erythropoietin) therapy for anemia of ESRD, 190-203
available forms of, 192
with CAD, 20-21
clinical effects of, *see* Clinical effects of rHuEPO therapy
dosing of, 193
with heart failure, 7, 8
history of, 47-48, 213-214
HTN and, 150-151, 196
pharmacology and routes of administration of, 192-193
physiology of endogenous EPO and, 190-192
public policy on, *see* Medicare end-stage renal disease program, rHuEPO therapy and
resistance to, 193-194
target Hgb of, 196-197
at Vicenza dialysis center, 351
see also rHuEPO therapy for anemia in dialyzed ESRD children and in CRI children
Ribavirin, 526
Riboflavin (vitamin B_2), 338
Rifampicin, 523
Rimaniadine, 526
Risk and risk factor(s)
of first acute rejection episode in pediatric renal transplantation, 503
for HIVAN, 395-398
of postrenal transplantation infections in children, 521
see also Risk and risk factor(s) for CV disease in renal disease
Risk and risk factor(s) for CV disease in renal disease
for acute coronary syndrome, 25
for arrhythmias, 57, 58
for atheroembolic renal disease, 44
for CIRF, 39-40
for dialysis pericarditis, 54
for percutaneous coronary intervention-related atheroembolic renal disease, 44
for ventricular arrhythmias, 58
see also Coronary revascularization in renal transplant candidates, risk and benefit of; Risk and risk factor(s) for heart failure in renal disease
Risk and risk factor(s) for heart failure in renal disease, 4-8
diabetes mellitus as, 4-5; *see also* Diabetic nephropathy
hyperhomocysteinemia as, 6
hypertension as, 5-6
reducing, 8
uremia and metabolic alterations as, 7
ventricular volume overload as, 6-7
Ritonavir, 389
Routes of rHuEPO administration, 192-193
RPF (renal plasma flow), adaptations of, to pregnancy, 173-176
RRTs (renal replacement therapies), *see* Dialysis; Renal transplantation

SAECG (signal-averaged electrocardiogram) for arrhythmias, 58
Saline hydration, prophylactic, for CIRF, 41-42
Salt wasting, and growth retardation in dialyzed ESRD children and in CRI children, 465
Saquinavir, 389
Schedules, dialysis, *see* Frequency, dialysis

Scintigraphy
nuclear, of CAD in renal disease, 15-17
two-compartment lymphoscintigraphy of cyclic idiopathic edema, 248-249
Second hit mutations, somatic, in *PKD1* and *PKD2* genes, 109-110
Secondary hyperparathyroidism, pathogenesis of, in pediatric renal osteodystrophy, 441-443
Secondary systemic hypertension (HTN) in urban HIV-infected patients, renal dysfunction related to, 386-387
Serum albumin, as index of nutritional status of children on CPD, 486
Serum markers for CAD in renal disease, 18
Serum phosphorus in pediatric renal osteodystrophy, 443-444
Severe ascites, practical approach to, 314
Sex of urban renal disease patients, effects of, on access to cardiac procedures, 367-376
Shunt for ascites in cirrhosis
peritoneovenous, 313
transjugular intrahepatic portosystemic, 167-168, 313
SIADH (syndrome of inappropriate secretion of antidiuretic hormone), V_2 receptor antagonists in, 271
Sickle glomerulopathy, patterns of, 340-341
Side effects, *see* Adverse effects
Signal-averaged electrocardiogram (SAECG) for arrhythmias, 58
Signal transduction in ADPKD, polycystin-1 and -2 and, 112
Singapore, *see* Dialysis for urban ESRD patients in Singapore, funding of, through charity
Sirolimus, 214-217
Skeletal resistance to PTH actions in secondary hyperparathyroidism of pediatric renal osteodystrophy, 443
SLE (systemic lupus erythematosus) in inner city residents, 339-340, 406-408
Smoking, urban renal disease and, 362
SNS (sympathetic nervous system), activation of, in HTN of ESRD, 150
Socioeconomic and racial factors in urban glomerular disease, 403-410
in FSGS, 405-406
HIVAN and, 403-404
in lupus nephritis, 406-408
Socioeconomic status of urban renal disease patients
and access to cardiac procedures, 367-376
effects of center and, on patient outcome, 356-361; *see also* Income-based disparities, effects of, on urban renal disease patient outcome
see also Socioeconomic and racial factors in urban glomerular disease
Sodium, *see* Na
Sodium bicarbonate (Na HCO_3), 431, 435
Sodium citrate, 435
Sodium nitroprusside, 336
Solute clearance on pediatric CPD, 481-483
clearance target in, 482-483
frequency of measurements of, 481-482
Somatic second hit mutations in *PKD1* and *PKD2* genes, 109-110
D,L-Sotalol for CV in renal disease, 58, 61, 68, 70
Soy protein for prevention of pediatric ADPKD progression, 431, 433
SPARC (secreted protein acidic and rich in cysteine) in tubulointerstitial injury, ANG II and, 554, 557-558
Spironolactone
for cirrhosis with ascites, 312, 314
for CV disease in renal disease, 9, 70, 71
for cyclic idiopathic edema, 249
for Na and water retention in CHF with cirrhosis, 157, 162, 167
progression of renal disease and, 547, 576
and renal apical Na^+ transporters, 86, 87
Spreading of cerebral edema, 305
ST segment, *see* Acute myocardial infarction with ST segment elevation in renal disease, management of
Starling Hypothesis of nephrotic edema, 266
States with highest number of AIDS cases, 396
Statins (β-hydroxy-β-methylglutaryl-coenzyme A reductase inhibitors), 20, 130, 351, 434-435
Statural growth of ESRD children on CPD, as index of nutritional status, 486-487
Steroids
in distal RTA, 97
in gestational hypertension, 182
for Na and water retention in cardiac failure with cirrhosis, 165
in nephrotic edema, 306
in renal transplantation, 182, 214-215, 508-510, 513-517, 523
for urban renal disease patients, 337
see also Steroids in renal transplantation
Streptokinase, 28
Stress echocardiography (stress test) of CAD in renal disease, 14-17
Structure
of Vicenza dialysis center, 346-347
see also Molecular structure
Sulfadiazine, 524
Supplementation for growth-retarded dialyzed ESRD children and in CRI children, 447, 464, 466
Supraventricular tachycardias (SVTs) in renal disease, 61-62
Survival
of CPD technique, and outcome of ESRD children on CPD, 485
see also Patient survival, inner city
SVT (supraventricular tachycardias) in renal disease, 61-62
Sympathetic nervous system (SNS), activation of, in HTN of ESRD, 150
Sympathomimetic amines in cyclic idiopathic edema, 249
Symptoms of CV disease in renal disease
of bradyarrhythmias, 62
of dialysis pericarditis, 55
see also Clinical features of CV disease in renal disease *and specific conditions*
Syncytial virus infections, postrenal transplantation respiratory, in children, 526
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), V_2 receptor antagonists in, 271
Systemic factors in edema of ARF, 251-252
Systemic hemodynamics
in cirrhosis with ascites, 308-309
unstable, in edema patients on HD, 287-228

Systemic lupus erythematosus (SLE) in inner city residents, 339-340, 406-408
Systemic primary and secondary hypertension (HTN) in urban HIV-infected patients, renal dysfunction due to, 386-387

T_3 (triiodothyronine) therapy, 246
T_4 (thyroxine) therapy, 246
Tachycardia in renal disease
  supraventricular, 61-62
  ventricular, 57-59
Tacrolimus, *see* FK506
Target clearances of solutes on pediatric CPD, 482-483
Target hematocrit, rHuEPO therapy, 457
Target hemoglobin (Hgb), rHuEPO therapy, 196-197
Taxanes, 431
T cell(s), nuclear factor of activated, as calcineurin target, 510-511
T-cell surface molecules, immunosuppression with, 513-514
Temisartan, 69
Tenofovir, 388
Terazosin, 69, 389
Terlipressin, 167
Testosterone, 247
Tetracyclines, 522
TGF-β, *see* Transforming growth factor-β; Transforming growth factor-β antisense oligonucleotides
Theophylline, 16
Theoretical basis of blood purification, 471-472
Therapeutic choices, informed, at Vicenza dialysis center, 348-349
Therapy and management
  of CHF with cirrhosis, 150, 162-163, 167-168
  of chronic renal insufficiency, *see* Pediatric chronic renal insufficiency and ESRD
  of diabetic and nondiabetic renal disease, genetic variability of RAS and, 586-588
  of HIVAN, 400-401
  of HTN in ESRD, 150-153, 193-194
  immunosuppressive, *see* Immunosuppression
  of pediatric postrenal transplantation infections, *see* Postrenal transplantation infections, pediatric
  of preeclampsia, 187
  preventive, *see* Prevention
  renal replacement, *see* Dialysis; Renal transplantation
  of UTO, 141-143
  see also Therapy and management of CV disease in renal disease; Therapy and management of diabetic nephropathy; Therapy and management of dRTA; Therapy and management of edema *specific therapeutic modalities; for example*: rGH therapy of dialyzed ESRD children *and specific drugs*
Therapy and management of CV disease in renal disease
  of arrhythmias, 58-63
  with atheroembolic renal disease, 44-45
  of CAD, 19-21
  of heart failure, 7-10
  preventive, of CIRF, 41-43
  of uremic pericarditis, 53, 55
  see also Acute myocardial infarction with ST segment elevation in renal disease, management of; Drug therapy of CV disease in renal disease; Non-Q wave myocardial infarction in renal disease, management of; Unstable angina in renal disease, management of
Therapy and management of diabetic nephropathy, 129-131
  antihyperlipidemic, 130
  blood glucose control in, 129
  HTN control in, 74, 126-129, 131
  protein restriction in, 130-131
  with renal and pancreas transplantation, 131
Therapy and management of dRTA, 102-105
  hyperkalemic dRTA, 104-105
  hypokalemic dRTA, 102-103
Therapy and management of edema
  in ARF, 254-255
  of ascites with edema, 311-314
  of cerebral edema, 306
  of cyclic idiopathic edema, 249
  of nephrotic edema, 266
Thiazide diuretics, *see* Diuretics
Thiazide-sensitive Na^+,Cl^- (NCC) cotransporter, genetic disorders of, 84-85
Thrombolytics (anticoagulants), 25, 28, 29, 33, 44, 60
Thyroid hormones in cyclic idiopathic edema, 246
Thyroxine (T_4) therapy, 246
Time pressure system in HD, defined, 473
Timolol, 69, 387, 389
TIPS (transjugular intrahepatic portosystemic shunt) for ascites in cirrhosis, 167-168, 313
Tirofiban, 32
Tissue plasminogen activator (t-PA), 28
Tissue renin-angiotensin system (RAS), and proinflammatory and profibrotic responses to renal injury, 596-597
TNF-α, *see* Tumor necrosis factor-α
Tocainamide, 389
Tocainide, 70
α (alpha)-Tocopherol (vitamin E), 187, 431
Tolerance, transplantation, 216-217
Torasemide, 255
Total body water in pregnancy, 178-179
Toxicity
  of digoxin in renal dysfunction, 72
  trace element intoxication on dialysis, 207-210
  see also specific drugs
Toxins, middle-molecular-weight uremic, and pediatric HD adequacy, 475-477
t-PA (tissue plasminogen activator), 28
Trace elements in dialysis, 207-210
Transcapillary exchange, normal, and β_1-integrins in P_{if}, 222-223
Transcellular urea mass transfer coefficient (Kie), defined, 476
Transepithelial fluid, secretion of, in ADPKD, 115-116
Transforming growth factor-β (TGF-β)
  in ADPKD, 436
  in chronic allograft nephropathy, 216
  in diabetic nephropathy, 126
  in glomerular disease, 403-405
  in UTO, 135-136, 140, 142, 143
  see also Hemodynamic-independent effects of ANG II receptor antagonists in fibrotic diseases
Transforming growth factor-β antisense oligodeoxynucleotides (TGF-β antisense ODN), 143

Transforming growth factor-β (TGF-β) in progression of renal disease
aldosterone and, 576, 577
fibrotic diseases, 563-567, 569-571
Transforming growth factor-β1 (TGF-β1) in progression of renal disease
aldosterone and, 577
in GS, 548-550
in tubulointerstitial injury, ANG II and, 554-557
Transjugular intrahepatic portosystemic shunt (TIPS) for ascites in cirrhosis, 167-168, 313
Transluminal coronary angioplasty, *see* Percutaneous transluminal coronary angioplasty in renal disease patients
Transplant glomerulopathy, pediatric renal transplantation chronic rejection and, 505
Transplantation
heart, BIA in, 282-285
liver, for hepatorenal syndrome, 56
renal, *see* Renal transplantation
Triamcinolone, 53
Triamterene, 70, 86
Triiodothyronine (T_3) therapy, 246
Trimethoprim-sulfamethoxazole, 342, 527
α (alpha)-Trinositol (D-myo-inositol-1,2,6-triphosphate), 225, 227
Trust in doctors of Mottep study participants, 425, 426
Tubular acidosis, *see* Distal renal tubular acidosis
Tubular disorders, *see* Renal apical Na^+ transporters, genetic disorders of
Tubular hypertrophy, tubulointerstitial injury and, 559-560
Tubular Na (sodium) reabsorption in cirrhosis, 323-326
Tubulointerstitial fibrosis
ANG II and, 554
and tubulointerstitial injury, 554
see also Tubulointerstitial fibrosis in UTO
Tubulointerstitial fibrosis in UTO, 135-140
nuclear factor-κB in, 139-140
TGF-α in, 135-136
TNF-α in, 136-137, 140, 142
Tubulointerstitial injury, *see* Angiotensin II in tubulointerstitial injury
Tumor necrosis factor-α (TNF-α)
HIVAN and, 405
and rHuEPO therapy, 193
in tubulointerstitial injury, ANG II and, 554, 558-559
in UTO, 136-138, 140, 142
Two-compartment lymphoscintigraphy of cyclic idiopathic edema, 248-249
Type I diabetes mellitus, *see entries beginning with terms*: Diabetes mellitus
Type II diabetes mellitus, *see entries beginning with terms*: Diabetes mellitus

UK (United Kingdom) study of rGH effects on dialyzed ESRD children adult height, 491-492
Ultrafiltration, *see* Hemodialysis for edema, proANPs and; Hemodialysis for edema in heart failure
Ultrasound (US)
intravascular, of CAD in renal disease, 18-19
see also Echocardiography of CV disease in renal disease
Underfilling theory of nephrotic edema, 263
Unifying hypothesis of body fluid volume regulation in CHF with cirrhosis, 158-159
United Kingdom (UK) study of rGH effects on dialyzed ESRD children adult height, 491-492
University-industrial complex, role of, in inner city neighborhood care, 331-332
Unstable angina in renal disease, management of, 25, 29-33
medical management of, 29-30
percutaneous coronary interventions and, 36
revascularization procedures for, 30-33
Urban renal disease
cocaine use and, 336, 357, 362-366
factors influencing urban renal disease patients' access to cardiac procedures, 367-376
introduction to, 327-328
see also Dialysis for urban ESRD patients in Singapore, funding of, through charity; Dialysis for urban ESRD patients at Vicenza center; HIV-associated nephropathy in urban population; Hypertension- and medication-related renal dysfunction in urban HIV-infected patients; Inner city renal disease patients, reflections on care of; Mottep model to increase donations and prevent need for transplantation in urban ESRD patients, assessment of; Patterns of inner city renal disease; Socioeconomic status of urban renal disease patients
Urea mass transfer coefficient, transcellular, defined, 476
Uremia
as risk factor for heart failure in renal disease, 7
see also Atrial natriuretic factors, adsorption of, in uremia; Dialysis; End-stage renal disease; Hypertension in ESRD; Pediatric chronic renal insufficiency and ESRD; Uremic pericarditis in renal disease; Renal transplantation; Uremic toxins *and entries beginning with acronym*: rHuEPO
Uremic pericarditis in renal disease, 52-54
in ARF, 53-54
in ESRD, 52-53
Uremic toxins, middle-molecular-weight, and pediatric HD adequacy, 475-477
Urinary concentration defects without polyuria, aquaporin-2 in, 236
Urinary tract malformations in UTO, 141
Urinary tract obstruction (UTO), 133-145
amiloride, lithium and, 98
apoptosis in, 138-139
effects of, on renal metabolism, 134
interstitial fibrosis in, *see* Tubulointerstitial fibrosis in UTO
oxidative stress in, 137-138
studies of, 140-141
therapy of, 141-143
Urodilatin, role of, in fluid regulation, 239-243
animal studies of, 240
conclusion on, 242
molecular mechanisms in, 239-240
physiology and pathophysiology of, 240-242
US, *see* Ultrasound
UTO, *see* Urinary tract obstruction

V_2 receptor agonists and V_2 receptor antagonists
hyponatremia corrected with, 269-273, 315
in Na and water retention in cardiac failure and cirrhosis, 157, 160, 167

Valsartan, 69, 74, 570
Vancomycin, 523, 524
Varicella zoster immunoglobulin (VZIG), 524-527
Varicella zoster infections, postrenal transplantation, in children, 525-526
Vascular access
  for pediatric HD, 472-474
  used at Vicenza dialysis center, 348
Vasodilators, 15, 16, 19, 43
  see also specific vasodilators
Vasogenic cerebral edema, 303-305
Vasopressin (antidiuretic hormone; arginine-vasopressin)
  in CHF with cirrhosis, 161-162, 164, 167
  in hypertensive pregnancy, 176-179
  in pathogenesis of nephrotic edema, 265
  regulation of aquaporin-2 trafficking by, 232-233
  role of, in cyclic idiopathic edema, 246
  see also V_2 receptor agonists and V_2 receptor antagonists
Venous needle, and extracorporeal circulation in HD, 473
Venovenous ultrafiltration, continuous, for edema of heart failure, 279-280
Ventricular arrhythmias
  in heart failure, 275
  in renal disease, 57-59
Ventricular contractions in renal disease, premature, 63-64
Ventricular dysfunction, *see* Left ventricular dysfunction, and heart failure in renal disease
Ventricular fibrillation (VF), 58, 59
Ventricular hypertrophy, *see* Left ventricular hypertrophy in renal disease
Ventricular tachycardia (VT) in renal disease, 57-59
Ventricular volume overload in heart failure, 6-7
Verapamil, 61, 75, 163, 389
VF (ventricular fibrillation), 58
Viral infections, pediatric postrenal transplantation, management of, 523-527
  CMV infections, 523-525
  EBV infections, 525
  hepatitis virus infections, respiratory syncytial virus infections, influenza infections, and parvovirus infections, 526
  polyoma infections and *Pneumocystis carinii* pneumonia infections, 527
  varicella zoster infections, 525-526
Vitamin B_2 (riboflavin), 338
Vitamin B_6 (pyridoxine), 20
Vitamin C (ascorbic acid), 187, 225
Vitamin D in ESRD, 151
  for growth-retarded dialyzed ESRD children and in CRI children, 464, 466, 467
  see also Vitamin D for pediatric renal osteodystrophy
Vitamin D for pediatric renal osteodystrophy, 444-447
  for dialyzed patients, 446-447
  effects of, on renal function, 446
  indications for, 447
Vitamin E (α-tocopherol) in preeclampsia, 187, 224
Volume
  continuous measurement of plasma, in HD patients, 288-289
  contrast agent, in percutaneous coronary interventions, 37-38
  ventricular, in heart failure, 6-7
  see also Blood volume; Fluid volume
VPA-985, clinical trial of, for hyponatremia of cirrhosis, 271
VT (ventricular tachycardia) in renal disease, 57-59
VZIG (varicella zoster immunoglobulin), 524-527

Waiting list, transplant, income and placement of urban renal disease patients on, 377-378, 381, 382
Warfarin, 60
Water
  free, and growth retardation in dialyzed ESRD children, 464-465
  quality of, in HD, defined, 471
  see also Congestive heart failure with cirrhosis, Na and water retention in; Edema; Total body water; Water balance; Water contaminants *and entries beginning with term*: Fluid
Water balance, aquaporin-2 and altered, in disease, 234-236
Water contaminants in HD, complications associated with, 471

Xenotransplantation, 217-218

Zalcitanine, 388
Zanamavir, 526
Zidovudine, 386-388
Zymosan, 225